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1ABSTRACT
Streptococcus pneumoniae is one of the most significant human bacterial
pathogens. It is a major causative agent of community-acquired pneumonia.
It  is  also the most common cause of  bacterial  otitis  media and among most
common  bacteria  causing  meningitis  in  children.   The  close  relatives  of S.
pneumoniae, the Viridans group streptococci form a central part of the human
oral microbiome, but they are also a leading cause of endocarditis. The fast and
reliable identification of these bacteria from clinical specimens would
therefore  be  of  prime  importance  for  a  clinical  microbiology  laboratory,
allowing  for  the  laboratory  to  provide  helpful  information  to  clinicians  for
identifying the infection focus and targeting antibiotic treatment.
The close relationship between S. pneumoniae and Viridans group
streptococci, especially their subgroup Mitis group streptococci, complicates
the reliable species level identification of these bacteria. The identification of
streptococci  by  the  traditional  biochemical  methods  is  both  unreliable  and
time-consuming: the identification takes 1-2 days after bacterial growth has
been detected on a plate or in a blood culture bottle. Even sequencing of the
16S ribosomal RNA gene commonly used as a reference method for bacterial
identification cannot reliably differentiate between pneumococci and other
Mitis group streptococci or identify other Mitis group streptococci to the
species level. For the identification of pneumococci, detection of
pneumococcal-specific genes is considered a “golden standard”. For the
Viridans  group  streptococci,  multi-locus  sequence  typing  (MLST),  based  on
the analysis of the sequences of several genes, is considered to be the most
reliable  method  of  identification.  However,  the  MLST  is  too  laborious  and
time-consuming for the identification of streptococci in a routine clinical
microbiology laboratory.
Within the last  decade,  MALDI-TOF mass spectrometry has enabled the
fast  and  reliable  identification  of  most  bacterial  species.  However,
exceptionally closely related bacterial groups pose a challenge even to the
MALDI-TOF technology. This holds true even for pneumococci and Mitis
group streptococci. In this study, the earlier database and algorithm versions
of  the  commonly  used  MALDI-TOF  systems  were  shown  to  be  unable  to
reliably differentiate between pneumococci and Mitis group streptococci.
Therefore, rapid molecular detection tests, such as GenomEra S.
pneumoniae™ evaluated in this study, are still needed for rapid detection of
pneumococci. However, it seems that the addition of more pneumococcal and
Mitis group strains in the databases and new interpretation algorithms allow
for reliable differentiation between pneumococci and the Mitis group
streptococci. Altogether, the combination of rapid gene detection tests and
2MALDI-TOF technology with enhanced databases and identification
algorithms enables fast, reliable and cost-effective differentiation between
pneumococci  and  Mitis  group  streptococci  and  the  reliable  group  level
identification  of  other  Mitis  group  streptococci.  This  is  a  sufficient  level  of
identification in a clinical microbiology laboratory, enabling the clinician to
evaluate  the  clinical  significance  of  the  finding  and  target  further
investigations and antibiotic treatment more specifically.
3TIIVISTELMÄ
Pneumokokki (Streptococcus pneumoniae) on merkittävimpiä ihmisen
bakteeripatogeenejä: se on merkittävä avohoitosyntyisen keuhkokuumeen ja
lasten välikorvatulehdusten aiheuttaja ja aiheuttaa myös suuren osan lasten
aivokalvontulehduksista. Sen lähisukulaiset, viridans-ryhmän streptokokit,
taas muodostavat merkittävän osan ihmisen suun normaalifloorasta, mutta
ovat myös keskeisiä sydänkalvontulehduksen aiheuttajia. Pneumokokkien ja
viridans-ryhmän streptokokkien nopea ja luotettava tunnistus kliinisen
mikrobiologian laboratoriossa olisi kuitenkin ensiarvoisen tärkeää, koska
tunnistustulos voi auttaa lääkäriä tunnistamaan infektiofokuksen ja
suuntaamaan antibioottihoidon oikein.
Pneumokokin ja viridans-ryhmän, erityisesti sen alaryhmän, mitis-ryhmän
streptokokkien lähisukulaisuus vaikeuttaa näiden bakteerien luotettavaa
erottamista toisistaan ja tunnistamista lajitasolle. Perinteisillä biokemiallisilla
tunnistusmenetelmillä pneumokokkien ja viridans-ryhmän streptokokkien
tunnistus vie yhdestä kahteen vuorokautta siitä, kun maljalla tai
veriviljelypullossa on havaittu bakteerikasvua. Edes bakteerien tunnistuksessa
yleisesti käytetty 16S rRNA-geenin sekvensointi ei kykene luotettavasti
erottelemaan pneumokokkeja mitis-ryhmän streptokokeista eikä viridans-
streptokokkeja lajitasolle. Pneumokokkien tunnistuksessa
referenssimenetelmänä käytetäänkin pneumokokeille tyypillisten geenien
monistusta. Viridans-ryhmän streptokokkien kohdalla tällaisena “kultaisena
standardina” käytetään usean geenin nukleiinihappojärjestyksen
analysointiin perustuvaa tyypitystä (MLST). Useiden geenien
sekvenssianalyysiin perustuva tunnistus on kuitenkin liian kallista ja aikaa
vievää kliinisen mikrobiologian laboratorion tarpeisiin.
Viimeisen vuosikymmenen aikana MALDI-TOF-massaspektrometria on
mahdollistanut useimpien bakteerien nopean ja luotettavan tunnistamisen.
Toisilleen poikkeuksellisen läheistä sukua olevat bakteerit ovat kuitenkin
haasteellisia tunnistettavia myös MALDI-TOF:lla. Tämä pätee myös
pneumokokkeihin ja Mitis-ryhmän streptokokkeihin. Tässä työssä osoitettiin,
että varhaisempia tietokantaversioita ja algoritmejä käytettäessä
tavallisimmin käytetyt MALDI-TOF-laitteistot eivät kyenneet luotettavasti
erottamaan pneumokokkeja Mitis-ryhmän streptokokeista. Tämän vuoksi
geenimonistustestit kuten tässä työssä arvioitu GenomEra S. pneumoniae™
ovat tarpeen pneumokokkien nopeassa osoituksessa. Tämän tutkimuksen
kolmas osatyö osoitti  kuitenkin,  että uusien pneumokokki-  ja  Mitis-ryhmän
streptokokkikantojen lisääminen ja uusien tunnistusalgoritmien
kehittäminen mahdollistavat pneumokokkien ja Mitis-ryhmän streptokokkien
luotettavan erottamisen toisistaan myös MALDI-TOF:lla. MALDI-TOF:n ja
nopean nukleiinihappotestin käyttö mahdollistavat pneumokokkien ja
4Viridans-streptokokkien nopean, luotettavan ja kustannustehokkaan
erottamisen sekä Viridans-streptokokkien luotettavan tunnistuksen
ryhmätasolle. Tämä tunnistustaso on riittävä kliinisen mikrobiologian
laboratorion tarpeisiin, sillä hoitava lääkäri pystyy sen perusteella arvioimaan
löydöksen kliinistä merkitystä ja kohdistamaan mahdollisia jatkotutkimuksia
ja antibioottihoitoa tarkemmin.
5ACKNOWLEDGEMENTS
I wish to thank my supervisor, Kaisu Rantakokko-Jalava for her invaluable
support during this research project. Her support has enabled me to work on
my research  alongside  my work  at  the  Clinical  Microbiology  Department  of
Turku  University  Hospital.  I  also  wish  to  thank  the  former  head  of  our
department, Olli Meurman, for his encouragement. The technical staff at the
Clinical Microbiology Department have provided skilful technical assistance,
especially Saana Viertomanner and Saija Vahanne, who carried out part of the
sample processing.
I also thank professor Per Saris for his guidance. I’m also indebted to Antti
Nissinen, who kindly agreed to act as my opponent, and to Susanna Lukinmaa-
Åberg  and  Sohvi  Hörkkö  for  their  insightful  comments  and  suggestions  for
revision.  I  also  especially  wish  to  thank  Roy  Siddall  and  David  Fewer  on
illuminating teaching on academic writing in English and encouraging
feedback  on  my  texts  that  helped  me  to  gain  necessary  confidence  in  my
writing  skills  that  enabled  me  to  complete  this  writing  process.  I  am  also
indebted to Professor Jaana Vuopio from University of Turku for her expert
advice  and  for  her  help  in  choosing  reviewers  and  opponents  for  my
dissertation.
Pauliina Kärpänoja and Hannu Sarkkinen deserve my warmest thanks for
their expert collaboration and for introducing me to the fascinating world of
clinical  microbiology  at  the  Clinical  Microbiology  Department  of  the  Päijät-
Häme  Central  Hospital  at  the  beginning  of  my  career  as  a  diagnostic
microbiologist. The technical knowledge of Cristoph Lange, Markus Kostrzewa
and Thomas  Maier  from Bruker  Daltonik  GmbH have  proved  invaluable  in
analyzing my data and constructing the list-score algorithm evaluated in the
last  paper.  I  also  wish  to  extend  my  thanks  to  Marjo  Haanperä  and  Maija
Toropainen from the Finnish Institute for Health and Welfare for performing
the molecular identifications for the mitis group streptococci and
pneumococci analysed in this study. Jari Hirvonen, Tapio Seiskari, Risto
Vuento and Janne Aittoniemi have been invaluable collaborators in the second
paper.
I  want  to  thank  head  of  the  Clinical  Microbiology  Laboratory  of  Turku
University Hospital Antti Hakanen and Erkki Eerola for their support in
securing the research funding necessary for writing this thesis. Juha Grönroos,
Niina Putkuri, Miia Laine, Eeva Sajanti, Piritta Peri, Marianne Gunell and
Kaisa Rantasärkkä receive my thanks for sharing my office and patiently
listening my ramifications concerning this project.
Last but not least I wish to thank my husband Tuukka and daughters Iiris
and Veera for their support and providing me with a healthy balance in my life.
I also wish to extend my thanks to my parents Matti and Tuula Harju for their
encouragement and stimulating my interest in science
6CONTENTS
Abstract………………………………………………………………………………….….1
Tiivistelmä…………………………………………………………………………………3
Acknowledgements……………………………………………………………………..5
Contents…………………………………………………………………………………….6
List of original publications ............................................................... …..8
Abbreviations ........................................................................................ ...9
1 Introduction ........................................................................................ 10
2 Review of the literature ...................................................................... 13
2.1 The genus Streptococcus…………………………………………………13
2.2 Taxonomy and classification……………………………………………13
2.3         Clinical significance……………………………………………………16
2.3.1 Infections caused by Streptococcus pneumoniae ...... 16
2.3.2        Infections caused by Viridans group streptococci..….18
     2.4       Virulence factors..………………………………………………….…….19
2.4.1 Virulence factors of Streptococcus pneumoniae……….19
2.4.2       Virulence factors of Viridans group streptococci………22
     2.5      Phylogeny of Streptococcus pneumoniae and Viridans group
                    streptococci………………………………………….…………………..25
     2.6       Identification methods………………………………………………..28
           2.6.1       Biochemical identification methods………………….…...28
           2.6.2       Pneumococcal serotyping………………………………………28
7           2.6.3       MALDI-TOF mass spectrometry…………………………….29
           2.6.4       Molecular diagnostics……………………………………….….34
3   Aims of the study…………………………………………………………………..38
4   Materials and methods…………………………………………………………..39
     4.1         Bacterial strains and culture methods…………………………….39
           4.1.1       Bacterial strains…………………………………………………….39
           4.1.2       Culture conditions…………………………………..................40
     4.2         Methods used in this study…………………………………………..41
           4.2.1       Biochemical identification methods………………………..41
           4.2.2       Pneumococcal serotyping……………………………………..42
           4.2.3       Identification with MALDI-TOF……………………………..42
           4.2.4       ABACUS GenomEra……………………………………………..45
           4.2.5       Pyrosequencing……………………………………………………46
           4.2.6       RecA gene sequencing………………………………………….46
5   Results…………………………………………………………………………………47
     5.1  The performance of  MALDI Biotyper and VITEK MS MALDI-
TOF  for identification of Viridans group streptococci (I)…. …………...…47
     5.2 The performance of MALDI Biotyper and ABACUS GenomEra™
S. pneumoniae test for differentiation of clinical pneumococcal and Mitis
group streptococcal strains (I, II, III)…………………………………………….…50
     5.3 The performance of ABACUS GenomEra™ Pneumococcus test
for detection of pneumococci directly from positive blood culture bottles
(III)…………................................................................................................51
6   Discussion……………………………………………………………...................52
7   Conclusions and future perspectives………………………………………..55
References………………………………………………………………………………..57
8LIST OF ORIGINAL PUBLICATIONS
This thesis is based on the following publications:
 I         Kärpänoja  P*,  Harju  I*,  Rantakokko-Jalava  K,  Haanperä  M,
Sarkkinen H. 2014. Evaluation of two matrix-assisted laser desorption
ionization-time of flight mass spectrometry systems for identification of
viridans group streptococci. Eur J Clin Microbiol Infect Dis. 33:779-788
II     Harju I, Lange C, Kostrzewa M, Maier T, Rantakokko-Jalava K,
Haanperä M. 2017. Improved differentiation of Streptococcus pneumoniae
and  other  mitis  group  streptococci  by  MALDI  Biotyper  using  an  improved
MALDI Biotyper database content and a novel result interpretation algorithm.
J Clin Microbiol. 55:914-922
*) Pauliina Kärpänoja and Inka Harju have contributed equally to this
study.
III      Hirvonen JJ,  Seiskari  T,  Harju I,  Rantakokko-Jalava K,  Vuento R,
Aittoniemi  J.  2015.  Use  of  an  automated  PCR  assay,  the  GenomEra  S.
pneumoniae, for rapid detection of Streptococcus pneumoniae in blood
cultures. Infect Dis (Lond). 47:796-800
The publications are referred to in the text by their roman numerals.
9ABBREVIATIONS
16S rRNA           16 small subunit ribosomal ribonucleic acid
bp                        base pairs
CAP                     community-acquired pneumonia
cps                       capsular polysaccharide
Da                        Dalton
DB                       database
Ddl                       D-alanine-D-alanine ligase
ESI-MS               Electron spray ionization – mass spectrometry
GPC                     gram-positive cocci
GroEL                 chaperonin-60
GroES                 chaperonin-10
IL                         interleukin
IVD                     in vitro diagnostics
LPA                     line probe assay
LytA                     pneumococcal autolysin
MALDI-TOF      matrix-assisted laser-desorption-ionization time-of-flight
MGS                    Mitis group streptococci
MLST                  multilocus sequence typing
NAAT                  nucleic acid amplification test
NASBA                nucleic acid sequence based amplification
PavA                    pneumococcal adhesion and virulence protein A
Ply                        pneumolysin
PCR                      polymerase chain reaction
PsaA                   pneumococcal surface antigen A
Psp                      pneumococcal surface protein
RecA                   subunit of bacterial recombinase
RNA                    ribonucleic acid
RnpB                  RNA subunit of endoribonuclease B
RpoB β-subunit of RNA polymerase
rpm                     rounds per minute
RUO                   research use only
SodA                   manganese-dependent superoxide dismutase
TNF-α                 tumour-necrotizing factor alpha
Tuf                       elongation factor Tu
VGS                     viridans group streptococci
VSB                      viridans streptococcal bacteraemia
VSSS                    viridans streptococcal shock syndrome
10
1 INTRODUCTION
The human microbiome has been the object of intense scientific interest in
recent decades.  The study of  human microbiome was long held back by the
limitations of bacterial culture methods. These limitations include the inability
of bacterial culture to detect small amounts of bacteria or the many bacteria
which cannot be grown in laboratory conditions due to their specific growth
requirements (Amann et al. 1995, Riesenfeld et al. 2004). The development of
molecular  methods  suitable  for  simultaneous  detection  of  hundreds  or
thousands  of  microbial  species,  such  as  shotgun  sequencing,  has  therefore
been instrumental for the study of the human microbiome (Kim et al. 2015).
Starting from 2000s, several large-scale projects were started in order to study
human microbiome. Among the largest of these international research
consortia  are  Metagenomics  of  the  Human  Intestinal  Tract  and  Human
Microbiome Project. According to the results gained in the Metagenomics of
the Human Intestinal Tract, it is estimated that there are over 1000 bacterial
species present in the human gut (Qin et al. 2010). In the Human Microbiome
Project the microbial diversity in a variety of body sites was studied (Human
Microbe Project Consortium 2012, Lloyd-Price et al.  2017).  In this  and in a
previous study by Costello et al. (2009) the human mouth was found to house
an exceedingly high variety of bacterial species, with the members of bacterial
genus Streptococcus dominant in most habitats within the human mouth.
From human perspective, the genus Streptococcus is  one  of  the  most
important bacterial  genera,  because it  includes some of  the most important
bacterial  pathogens  as  well  as  central  members  of  the  healthy  human
microbiome. The best-known members of the genus Streptococcus are
pathogenic organisms such as pyogenic streptococci that cause tonsillitis,
erysipelas, wound infections and bacteraemia and are traditionally typed
according to the Lancefield antigens they present, such as A, C or G. Another
important  member  of  the  genus  is Streptococcus agalactiae, presenting
Lancefield antigen B and most typically causing bacteraemia in the new-born
babies. All these streptococci present a clear zone around the colonies when
growing  on  blood  agar  plates.  This  clearing  is  caused  by  cytotoxins
(streptolysins) secreted by these bacteria lysing red blood cells in the agar. This
phenomenon is called beta-haemolysis and these pathogenic streptococci are
duly called beta-haemolytic streptococci.
However, there is another pathogen within the genus Streptococcus that is
also of prime importance as a human pathogen: Streptococcus pneumoniae.
Unlike pyogenic streptococci, S. pneumoniae does  not  produce  the  typical
clear  zone  around  its  colonies  on  blood  agar  but  rather  a  faintly  greenish
colouring diffused into the agar surrounding the colony. This phenomenon is
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called alpha-haemolysis and is caused by the streptococci producing hydrogen
peroxide,  which  oxidizes  the  haemoglobin  in  the  blood  agar  to
methaemoglobin. Despite its lack of beta-haemolysis, S. pneumoniae can
cause infections using other virulence factors, such as pneumococcal autolysin
(LytA) and the pneumolysin (Ply) (Alonso de Velasco et al. 1995, Jedrzejas
2001). S. pneumoniae is an important causative agent of community-acquired
pneumonia and bacterial otitis media. It also causes a significant proportion
of cases of meningitis (Krzyściak et al. 2013, Feldman et al. 2014).
Despite its virulence, S. pneumoniae is  more  closely  related  to  alpha-
haemolytic Viridans group streptococci (VGS) than to the beta-haemolytic
streptococci. VGS are an integral part of the healthy human microbiome in the
respiratory, gastrointestinal and urogenital tracts. Although VGS are mostly
commensal, they can also cause infections, most notably endocarditis,
predominantly in patients with predisposing factors (Doern and Burnham
2010, Krzyściak et al. 2013). The  VGS  are  divided  into  five  groups:
Streptococcus anginosus, Streptococcus bovis, Streptococcus mitis,
Streptococcus mutans and Streptococcus salivarius (Kawamura et al. 1995,
Spellerberg et al. 2011). Of all the VGS groups, the taxonomy of the S. mitis
group has perhaps been most challenging: in addition to twelve closely related
commensal species of the upper respiratory tract it also contains the important
pathogen S. pneumoniae that  is  phylogenetically  close  to  these  commensal
species.
In clinical microbiology laboratories, in which pathogenic microbes are
isolated  and  identified  from  patient  samples,  VGS  have  traditionally  been
differentiated from pneumococci based on their optochin resistance and lack
of  bile  solubility,  as  well  as  by  using  commercial  biochemical  test  panels.
However, Ikryannikova et al. (2011)  has  reported  misidentification  of
optochin-susceptible S. mitis strains as S. pneumoniae. Commercial
biochemical test panels have also been shown to be limited in their ability to
identify streptococci reliably to the species level (Bascomb and Manafi 1998,
Summanen et al., 2009, Chatzigeorgieau et al., 2011, Teles et al. 2011).
Biochemical identification methods are also time-consuming, generally taking
1-2 days to complete.
The advent of molecular methods has enabled more reliable identification
of  many  clinically  relevant  bacteria.  However,  the  sequencing  of  16S  rRNA
gene,  which  is  widely  used  as  a  reference  identification  method  in
microbiology, has been proven to be of limited use in the species identification
of VGS species, because of the tight interrelatedness of these species
(Haanperä et al.  2007).  Because  of  limitation  of  the 16S rRNA sequencing,
multi-locus sequence typing (MLST) approach targeting several streptococcal
housekeeping genes (Kawamura et al. 1999, Whatmore et al. 2000, Hoshino
et al.  2005,  Chi et al. 2007, Kilian et al.  2008,  Do et al.  2009)  has  been
established as a golden standard for streptococcal identification and
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phylogenetic studies. Genes conferring to virulence in pneumococci have also
been  targeted  for  development  of  various  nucleic  acid  amplification  assays
(NAATs) in order to identify pneumococci isolated from cultured clinical
samples (Rudolph et al. 1993, Domiguez et al. 2001).
Because NAATs still remain relatively expensive, there has been wide
interest in assessing the potential of matrix-assisted laser
desorption/ionization-time of flight (MALDI-TOF) mass spectrometry, which
in recent years has established itself as fast and cost-effective identification
method in clinical microbiology laboratories (Seng et al. 2009, Bizzini et al.
2010, Neville et al. 2011). Although the instrument cost of MALDI-TOF mass
spectrometry is  high,  the reagent costs  are very low compared to molecular
methods, and only minimal hands-on time is required. However, the greatest
benefit of MALDI-TOF technology for a clinical microbiology laboratory is that
it is possible to acquire bacterial identification within minutes compared to
one or two days typically required by traditional biochemical methods. Such
rapid diagnostic methods are especially important in a clinical laboratory
setting,  where  laboratory  diagnosis  can  have  direct  impact  on  the  patient
receiving effective treatment.
Identification of Streptococcus pneumoniae and VGS by MALDI-TOF MS
has been widely studied (van Veen et al. 2010, de Bel et al. 2010, Neville et al.
2011, Scholz et al. 2012, Martiny et al. 2012, Werno et al. 2012, Davies et al.
2012, Lopez Roa et  al. 2013, Ikryannikova et al. 2013, Dubois et al. 2013,
Branda et  al. 2013, Woods et al. 2014, Angeletti et  al. 2015, Isaksson et  al.
2015). However, the differentiation of S. pneumoniae and other Mitis group
streptococci, especially S. mitis and S. pseudopneumoniae has proven
challenging.  Researchers have suggested potential solutions to this problem;
such  as  expanding  the  databases  of  these  MALDI-TOF  systems  to  include
recently described Mitis group species such as Streptococcus tigurinus
(Isaksson et al. 2015) and improving the algorithms used to calculate closest
matches (Rychert et al. 2013, supplementary material).
In  this  study,  we  aimed  to  assess  rapid  commercial  methods  for  their
potential for fast, reliable and cost-effective identification of S. pneumoniae
and VGS in a routine clinical microbiology laboratory. The performance of two
MALDI-TOF systems,  MALDI Biotyper and VITEK MS, for identification of
VGS were compared. We also evaluated the effect of using a novel algorithm
utilizing “list scores” combined with the addition of new streptococcal strains
to the database to the ability of MALDI Biotyper to differentiate between
pneumococci and Mitis group streptococci. Furthermore, the potential of a
commercial NAAT, GenomEra Pneumococcus™, for rapid identification of S.
pneumoniae directly from positive blood culture bottles was investigated.
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2 REVIEW OF THE LITERATURE
2.1 THE GENUS STREPTOCOCCUS
The genus Streptococcus comprises catalase-negative gram-positive cocci,
typically occurring in chains or pairs. It is one of the clinically most important
bacterial  genera.  It  contains  important  pathogens  such  as Streptococcus
pyogenes and Streptococcus pneumoniae as  well  as  numerous  members  of
healthy human microbiota. Streptococci have traditionally been divided into
pyogenic  and  viridans  streptococci  based  on  the  type  of  haemolysis  they
produce  on  blood  agar  plates.  So-called  pyogenic  streptococci  such  as S.
pyogenes, Streptococcus dysgalactiae, Streptococcus agalactiae and
Streptococcus equi can  cause  infections  in  humans  and/or  animals  and
produce a clearing of  the agar around their  colonies,  called beta-haemolysis
(Spellerberg and Brandt 2011).
Conversely, the viridans group streptococci contain mostly species
belonging to the healthy human microbiota, especially in the mouth and upper
respiratory tract. The name viridans group streptococci refers to the greenish
coloration, called alpha-haemolysis, which these bacteria often develop
around  their  colonies.  However,  this  alpha-haemolysis  is  not  typical  for  all
species  within  this  group.  Many  VGS  species  form  also  non-haemolytic  or
beta-haemolytic  colonies.  Members  of  the Streptococcus anginosus group
may present the Lancefield antigens A, C and G typical for the pyogenic
streptococci and members of the Streptococcus bovis group may exhibit the
Lancefield antigen D also present in enterococci (Doern and Burnham 2010,
Spellerberg and Brandt 2011). In addition to commensal and only
opportunistically pathogenic species, the viridans group also includes the
important pathogen S. pneumoniae.
2.2 TAXONOMY AND CLASSIFICATION
The taxonomy of  streptococci  has been in flux since the start  of  modern
bacteriology, taxonomical changes continuously spurred by technical
developments in streptococcal typing and identification. In 1937, Sherman
suggested  dividing  the  organisms  then  classified  as  streptococci  into  four
groups: pyogenic streptococci, viridans streptococci, lactic streptococci and
enterococci. He excluded pneumococci on the basis of their bile-solubility, the
members of the genus Leuconostoc because of their lactic-acid production and
obligate anaerobic gram-positive cocci, then grouped as “anaerobic
streptococci” but now considered to belong to several different genera such as
Peptostreptococcus, Finegoldia and Micromonas. Sherman’s groupings into
pyogenic and viridans streptococci are still relevant today, but strains showing
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phenotypical characteristics similar to his enterococcus group are nowadays
classified into the genus Enterococcus with the advent of 16S rRNA sequencing
(Schleifer et al. 1984, Ludwig et al. 1985).  Similarly,  the  two  species  of  his
“lactic streptococci” group were moved into the new genus Lactococcus in the
1980s, also based on the comparison of 16S rRNA sequences by Schleifer et al.
(1986).  Sherman’s classification was based on whether the strains presented
a clearing around the colonies known as beta-haemolysis (first described by
Schottmüller  in  1903  and  Brown in  1919  in  publications  that  are  no  longer
readily available, Facklam 2002) and on specific antigens presented by beta-
haemolytic  streptococci  reported  by  Lancefield  in  1933,  as  well  as  salt  and
thermal  tolerance  along  with  other  biochemical  properties.  Detection  of
haemolysis  and  Lancefield  antigen  typing  remain  a  cornerstone  for
identification of beta-haemolytic even today, but reliable identification of VGS
and pneumococci has remained challenging ever since Sherman’s days.
The taxonomical classification within VGS has seen several upheavals since
the  1990s,  mainly  due  to  the  advent  of  modern  molecular  typing  methods
(Facklam 2002, Arbique et al., 2004, Doern et al. 2010, Spellerberg and
Brandt 2011). Currently, the VGS are divided into five groups: Streptococcus
anginosus, Streptococcus bovis, Streptococcus mitis, Streptococcus mutans
and Streptococcus salivarius on  basis  of  comparison  of  16S  rRNA  gene
sequences (figure 1) (Kawamura et al. 1995, Whiley et al. 1998, Spellerberg et
al. 2011). Other researchers basing their groupings more on phenotypic
characters have, however, distinguished Streptococcus sanguinis,
Streptococcus parasanguinis and Streptococcus gordonii from other mitis
group  streptococci,  to  which  they  are  related  based  on  their  16S  rRNA
sequences, into a separate Streptococcus sanguinis group (Facklam 2002,
Doern and Burnham 2010).
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Figure 1. Subgroups of Viridans group streptococci
The first description of the Streptococcus mitis was presented by Andrewes
and Horder in 1906 based on the phenotypical  characteristics  that  could be
studied  with  the  methodology  available  at  the  time.  They  classified  into
Streptococcus mitis group commensal streptococci that formed short chains
and grew well at 20°C and were able to ferment both lactose and sucrose and
which,  in  contrast  to  the  other  VGS  species  he  named Streptococcus
salivarius, were usually unable to curdle milk or ferment inulin or raffinose.
Although  none  of  the  strains  studied  by  Andrewes  and  Horner  have  been
preserved, Kilian et al. (1989  (1))  have  speculated  that  the  strains  they
designated as S. mitis were likely to comprise several of the currently
recognized streptococcal species.
In 1943 Sherman et al. criticized the existing species descriptions within
VGS for  their  vagueness:  “As  compared  with  the  other  major  groups  of  the
genus, the taxonomy of the viridans streptococci is in a highly unsatisfactory
condition; but the common impression that the viridans streptococci compose
a hopelessly heterogeneous conglomeration is largely due to the general failure
to determine the basic nature of the organisms dealt with.” On basis of their
comparison  of  biochemical  and  morphological  properties  between  VGS,
Sherman concluded that although S. mitis group displayed relatively
heterogeneous phenotypical properties, its members could still be reliably
distinguished from S. salivarius and other recognised VGS. Although he was
unable to ascertain it due to the lack of knowledge on the nature and mode of
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transfer of genetic information at the time, Sherman hypothesised that S. mitis
group was likely comprised of several species.
Despite Watson and Crick deciphering the structure of deoxyribonucleic
acid (DNA) in 1953, the use of genetics in bacterial phylogenetic studies really
took  off  only  in  the  1980s  after  the  development  of  the  polymerase  chain
reaction  (PCR)  that  enabled  the  amplification  of  DNA  so  that  it  could  be
feasibly studied (Saiki et al. 1985, Mullis et al. 1986, Saiki et al. 1988).
However, Coykendall et al.  (1978)  and  Gilmour et al. (1987)  studied  the
phylogenetic relationships among the S. mitis group using DNA-DNA
hybridization and multilocus enzyme electrophoresis even before the advent
of PCR-based methods.
The S. mitis group currently includes the important pathogen S.
pneumoniae and twelve other validly described species: S.  australis,   S.
cristatus (formerly S. crista), S. gordonii, S. infantis, S. mitis, S.
oligofermentans, S. oralis, S. parasanguinis (formerly S. parasanguis), S.
peroris, S. pseudopneumoniae (Arbique et al. 2004), S. sanguinis (formerly
S. sanguis) and S. sinensis (Spellerberg and Brandt 2011). Furthermore,
recently described species S. dentisani (Camelo-Castillo et  al. 2014) and S.
tigurinus (Zbinden et  al. 2012)  seem  to  belong  to  the  mitis  group  as  well.
Recently, Jensen et al. (2016) have suggested re-evaluation of the taxonomy
of the S. mitis group, based on whole-genome analyses. They have proposed
reclassification of Streptococcus dentisani as Streptococcus oralis subsp.
dentisani comb. nov., Streptococcus tigurinus as Streptococcus oralis subsp.
tigurinus comb. nov. and Streptococcus oligofermentans as a later synonym
of Streptococcus cristatus.
2.3 CLINICAL SIGNIFICANCE
2.3.1 INFECTIONS CAUSED BY STREPTOCOCCUS PNEUMONIAE
Streptococcus pneumoniae is one of the most important bacterial
pathogens. Asymptomatic pneumococcal carriage in the nasopharynx is very
common, especially in children. In a recent study by Hamaluba et al. (2015),
47 % of children, 9 % of parents of small children and 2.2 % of older adults
were  found  to  be  carriers.  The  elderly  individuals  also  seem  to  be  more
susceptible  to  pneumococcal  colonization,  at  least  in  the  rat  model
(Theravanjan et al.  2016).   However,  it  is  also  among the  leading  causative
organisms of such important invasive infections as community-acquired
pneumonia (CAP), pneumonia in young children (especially important in
developing countries), meningitis in young children and otitis media
(Feldman et al. 2014). These invasive pneumococcal infections can also lead
to  bacteraemia,  in  which  the  pathogenic  bacteria  spread  through  the  blood
stream. According to the infectious diseases statistics compiled by the
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National Institute of Health and Welfare there were in the year 2018 over 800
diagnosed cases of invasive pneumococcal infections in which S. pneumoniae
had been  isolated  from blood  or  cerebrospinal  fluid  (www.thl.fi, referred in
28.3.2019). Of the non-invasive pneumococcal infections, the most significant
is by far otitis media, which is very common in young children and causes a
significant burden to health-care systems both in developing and developed
countries.
Pneumonia  is  one  of  the  most  common  infectious  causes  of  death
worldwide (Lozano et al. 2012). In the latter half of the 20th century, mortality
rate in bacteremic CAP has been estimated to have been on average 12 %
(Ludwig et al. 2012). The incidence of pneumococcal pneumonia is probably
underestimated due to diagnostic difficulties: the pathogen is detected only in
bacteremic cases, unless special tests such as urine pneumococcal antigen tests
are performed (Said et al.  2013).  However,  the  use  of  these  antigen  tests  is
limited to adult patients, since high rates of nasal pneumococcal carriage in
children  can  result  in  false  positive  reactions  (del  Mar  García-Suarez et al.
2007).
Pneumococci often causes secondary bacterial respiratory infections in
patients with influenza (Chertow et al. 2013). This is illustrated by Cilloniz et
al. (2012), Martin-Loeches et al. (2011), Rice et al. 2012 and Muscedete et al.
(2013) who have reported increased rates of community-acquired pneumonia,
often  caused  by  pneumococci,  in  patients  infected  with  H1N1  influenza  in
2009.
In the Global Burden of Disease Study 2013 Vos et al. (2015) estimated the
global prevalence of pneumococcal meningitis in 2013 to have been between 5
million and 11 million and to have caused between 500 000 and 900 000 years
lived with disability, mainly because of hearing loss and intellectual disability.
S. pneumoniae was also estimated to be the most common causative agent of
meningitis worldwide in 2013.  In the same study, pneumococcal meningitis
was placed fifth among the identifiable causes of intellectual disability
worldwide after neonatal encephalopathy due to birth asphyxia and trauma,
unbalanced chromosomal rearrangements, preterm births complications and
Down  syndrome.  It  was  also  estimated  to  be  the  most  common  infectious
cause of intellectual disability. Vos and collaborators also estimated otitis
media to be the most common and pneumococcal meningitis the second most
common infective cause of hearing impairment worldwide.  Vos et al.  (2015)
also estimated that pneumococcal meningitis had caused 35 000 years lived
with disability for visual impairment.
Otitis media is one of the most common childhood infections. Otitis media
is often preceded by viral upper respiratory infections that facilitate the
invasion  and  infection  of  the  middle  ear  caused  by  bacterial  pathogens  as
Streptococcus pneumoniae, Haemophilus influenzae and Moraxella
catarrhalis that are common residents of the nasopharynx in young children
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(Ruuskanen et al.  2003).  In  developed  countries  otitis  media  is  usually
effectively treated with antibiotics, therefore serious sequelae are rare in these
countries. However, in developing countries, adverse outcomes of untreated
otitis media are common, often resulting in some degree of hearing loss. In the
Global  Burden of  Disease Study 2013 Vos et al. (2015) estimated the global
prevalence of otitis media in 2013 to have been about 85 million and to have
caused between 1  million and 2.7 million years lived with disability,  mainly
because of hearing impairment. A significant portion of these infections can
be assumed to be caused by pneumococci.
2.3.2 INFECTIONS CAUSED BY VIRIDANS GROUP STREPTOCOCCI
Viridans  group  streptococci  form  an  integral  part  of  the  human
microbiome. Members of S. mitis, S. mutans and S. salivarius groups typically
colonise  the  oral  cavity,  whereas  members  of S. bovis group inhabit the
intestine and members of S. anginosus group  can  be  found  both  in  the
oropharynx and in the intestine. S. mutans is  well-known for its  role in the
pathogenesis of dental caries (Krzysciak et al. 2014), but other members of the
VGS are a part of the normal human oral and intestinal bacterial flora. They
can,  however,  cause  serious  infections  in  immunocompromised  hosts  or  in
patients with underlying heart disease.
According to Pant et al. (2015) Streptococcus species were the second most
common causative organisms of infective endocarditis in the US 2000-2011
after Staphylococcus species. Gupta et al.  (2016) reported that this was also
the case for children in the US 2010-2011. In the same article, Gupta et al. also
reported that VGS were still the most common causative organisms in children
with underlying heart disease.
The frequency of streptococcal endocarditis has decreased in the past 50
years in developed countries, whereas the incidence of infective endocarditis
caused by Staphylococcus and Enterococcus species has increased, which
might  be  connected  with  the  increased  use  of  intravascular  catheters  and
prosthetic vascular grafts in the case of coagulase-negative staphylococci,
increased intravenous drug abuse in the case of Staphylococcus aureus and
increased median patient age and increased prevalence for diabetes for
Enterococcus species (Slipczuk et al. 2013). In a review by Elder et al. (2015)
it  was noted that  in paediatric  patients the proportion of  VGS as a cause of
infective endocarditis had steadily decreased since the 1950s. They attributed
this relative reduction to the improved surgical treatment options for
congenital heart diseases and the decreased incidence of rheumatic fever and
rheumatic heart disease resulting from it.
The role of VGS in causing invasive infections in patients treated for cancer
with chemotherapy was first highlighted by Pizzo et al. in 1978 for adults and
Hoecker et al. in  the  same  year.  The  damage  to  mucous  membranes  and
granulocytopenia  induced  by  chemotherapy  allowed  VGS  to  cause  invasive
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infection when entering the blood stream from damaged mucosal membranes.
Transient  VGS  bacteraemia  (VSB)  is  common  in  connection  with  dental
treatment or periodontal disease, but immunocompetent hosts can quickly
clear  it.  VSB  has  also  been  found  to  be  an  important  problem  in  stem  cell
transplant recipients (Henslee et al. 1984, Bilgrami et al. 1998). VGS
bacteraemia has been studied in paediatric patients with acute myeloid
leukaemia in recent years (Brunet et al. 2006, Johannsen et al. 2013, Lewis et
al. 2014). Nielsen et al.  (2016) found also the children suffering from acute
lymphoblastic leukaemia to be at high risk of VSB.
Han et al.  (2006)  has  investigated  the  species  variety  and  antibiotic
susceptibility of the VGS isolated from blood cultures of cancer patients and
has  found out  that S. mitis was the most common species. In this study, S.
mitis also displayed more resistance to penicillin and fluoroquinolones than
strains  belonging  to  other  VGS  species. S. mitis was  also  shown  to  cause  a
disproportionately high percentage of bacteraemia accompanied by viridans
streptococcal  shock  syndrome  (VSSS)  both  in  Han’s  study  and  in  a  study
published by Shelburne et al. in 2014. S. mitis was  also  the  most  common
causative  organism in  all  the  eight  VSSS cases  in  paediatric  cancer  patients
reported by Nielsen et al. (2016).  In VSSS the patient develops hypotension
and/or acute respiratory distress syndrome. The mortality  rate of  VSSS has
been reported to range from 0 % to 37 % (Gassas et al. 2004, Nielsen et al.
2016).
2.4   VIRULENCE FACTORS
2.4.1 VIRULENCE FACTORS OF STREPTOCOCCUS PNEUMONIAE
Streptococcus pneumoniae colonises  the  mucous  membranes  of  the
oropharynx of more than 60 % of healthy people (Mitchell et al. 2003) but can
cause disease when it gains access to the middle ear, the lower respiratory tract
or the brain. For successful oropharyngeal colonisation S. pneumoniae needs
the  ability  to  adhere  to  the  mucosal  surfaces.  In  addition,  in  order  to  cause
disease S. pneumoniae needs several virulence factors that allow it to attach to
the  host  cells,  invade  the  host  tissues  and  avoid  the  host  immune  system.
(Alonso de Velasco et al. 1995, Jedrzejas et al. 2001, Mitchell et al. 2003). The
virulence factors of S. pneumoniae and Viridans group streptococci are also
central to this study because the genes encoding for pneumococcal virulence
factors  have  been  the  principal  targets  of  most S. pneumoniae nucleic acid
amplification  assays.  It  is  therefore  important  to  be  aware  to  which  extent
these virulence factors are shared by S. pneumoniae and  VGS  in  order  to
ascertain the specificity of these nucleic acid amplification tests.
The polysaccharide capsule is considered to be one of the main virulence
factors of S. pneumoniae. The polysaccharide capsule is believed to impair the
phagocytosis by neutrophils (Jonsson et al. 1985, Hyams et al.  2010)  by
reducing complement deposition, inhibiting CRP binding and covering
20
antigens on the pneumococcal cell surface (Skov-Sorensen et al. 2016). Magee
et al. (2001) and Nelson et al. (2007) also found out that the S. pneumoniae
strains that lacked the polysaccharide capsule were less efficient in colonising
the  mucosal  surfaces.  The  extreme  diversity  of  the  capsular  polysaccharide
helps  the  pneumococci  to  evade  the  human  immune  system  by  cycling  the
capsular antigens that the human antibody-response is largely targeted to. The
differences in the capsule polysaccharide are also the basis of pneumococcal
serotypes that are important for pneumococcal epidemiology and vaccine
development. Before the advent of antibiotic treatment, the serotyping of
pneumococci was also crucial for anti-serum treatment of pneumococcal
infections (Geno et al. 2015). Currently, there are 98 recognised pneumococcal
capsular serotypes (Skov-Sorensen et al. 2016, Geno et al. 2017). Infection
with different pneumococcal serotypes together with the different host factors
are  also  known  to  generate  variant  cytokine  profiles,  although  common
themes in these profiles can also be found in all pneumococcal lung infections
in a mice model (Jonczyk et al. 2016)
In addition to the polysaccharide capsule, the pneumococcal cell wall is also
important for pathogenesis. In addition of helping with the attachment to lung
cells (Cundell et al. 1995), the cell wall of S. pneumoniae also plays a role in
the development of the inflammation in invasive pneumococcal infections
(Tuomanen et al. 1985). The fact that the phosphorylcholine contained in the
pneumococcal cell wall binds to the receptor of the platelet-activating factor
might also partly explain why pneumococcal pneumonia so often develops
after viral infection, since the platelet-activating factor is activated during viral
infections (Ishizuka et al. 2003, Mitchell 2003).
Pneumococcal  surface  proteins  also  play  an  important  role  both  in
pneumococcal colonisation pathogenesis. The pneumococcal surface proteins
are  divided  into  three  groups  based  on  their  linkage  to  the  cell  surface:
LPXTG-anchored proteins, lipoproteins and choline-binding proteins
(Mitchell et al. 2003). LPXTG-anchored proteins derive their name from how
they  are  anchored  to  the  cell  wall  using  an  LPXTG-type  amino-acid  motif.
Neuraminidase  and  hyaluronidase  are  among  the  most  important  of  these
proteins. Neuraminidase seems to play a role in the nasopharyngeal
colonisation by S. pneumoniae (Tong et al. 2000). Hyaluronidase can break
down the hyaluronic-acid in connective tissue and extracellular matrix and has
been  found  to  augment  pneumolysin-mediated  injury  to  human  ciliated
epithelium (Feldman et al. 2007).
The pneumococcal lipoproteins considered to be most important for
adhesion and pathogenesis are pneumococcal surface antigen (PsaA) and
pneumococcal  adhesion  and  virulence  protein  A  (PavA).  PsaA  is  part  of  a
manganese-transport chain (Lawrence et al. 1998) and has been found to have
the potential to assist in the invasion of the blood stream by S. pneumoniae
(Hu et al. 2013). Mutants lacking the psa and Mn2+ transport, have been found
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to be unable to cause infection (Marra et al. 2002). PavA is a protein present
on the pneumococcal cell surface and is known to associate with fibronectin
(Mitchell 2003). Kadioglu et al.  (2010)  conclude  that  PavA  is  involved  in
successful pneumococcal colonization of mucosal surfaces and in
translocation of pneumococci across host barriers, making it important both
for establishing nasopharyngeal colonisation and in invasive infections.
The most important pneumococcal virulence factors among the choline-
binding  proteins  are  autolysin  (LytA)  and  pneumococcal  surface  proteins  A
and C (PspA and PspC). The pneumococcal autolysin is involved in releasing
pneumolysin out of the cell (Mitchell 2003). PspA is expressed by all clinically
important pneumococcal serotypes and is highly variable among them (Crain
et al.  1990).  Both  PspA  and  PspC  have  been  found  to  interfere  with  the
functioning of the human complement system (Mitchell et al. 2003). Mutant
strains  lacking  PspA  and  PspC  have  been  found  to  have  reduced  ability  to
adhere  to  the  nasopharyngeal  surfaces  and  to  translocate  to  the  lungs  and
bloodstream (Ogunniyi et al. 2007). Quin et al. (2007) reported also that the
PspA  and  PspC  deficient  mutant  were  cleared  from  the  bloodstream  more
easily than non-mutated strains. Keller et al.  (2016)  found  that  a  triple
deletion of the common virulence factors PspA, PspC, and Ply completely
impaired virulence in the chinchilla otitis media model.
Pneumolysin  is  a  cytoplasmic  pore-forming  toxin  released  from
pneumococcal  cells  by autolysin during pneumococcal  autolysis  and growth
(Mitchell and Mitchell 2010). Pneumolysin has been found to contribute to the
pathogenesis of pneumococcal infections in several animal models (Mitchell
et al. 2003, Hirst et al. 2004 and Zafar et al. 2017). Zafar et al. (2017) found
that pneumolysin increased inflammation and pneumococcal shedding in
mouse pups and also improved the environmental survival of S. pneumoniae,
therefore  allowing  for  more  efficient  transmission  from  one  mouse  pup  to
another.
Pneumolysin can induce inflammation by boosting the production of
inflammatory cytokines such as tumour-necrotizing factor alpha (TNF-α) and
interleukins IL-1β (Houldsworth et al. 1994), IL-8 (Cockeran et al. 2002,
Lüttge et al. 2012) and IL-17 (Basset et al. 2007). Pneumolysin is also known
to be able to activate the complement system (Mitchell et al. 2003). These
effects may be behind its association with increased infiltration of neutrophils
into the lungs outlined in Hirst et al. (2004).  Pneumolysin plays a role in the
evasion  of  the  immune  system  by  pneumococci  (Quin et al.  2007),  which
might result partly from its cytotoxic effects on leukocytes. Gilley et al. (2016)
noticed that pneumococci invading the myocardium kill infiltrated
macrophages by pneumolysin-mediated necroptosis. Pneumolysin is also
toxic  to  both  pulmonary  endothelial  (Rubins et al. 1992) and epithelial
(Rubins et al. 1993) cells. As a pore-forming toxin, pneumolysin can perforate
lipid  membranes  of  epithelial  and  endothelial  cells.  This  allows  it  to  impair
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their barrier function within the blood vessels (Mitchell and Mitchell, 2010).
Braun et al.  (2007) found that  pneumolysin could cause the death of  nerve
cells by impairing the function of their mitochondrial membranes.
2.4.2 VIRULENCE FACTORS OF VIRIDANS GROUP STREPTOCOCCI
Of all the VGS species, the virulence factors of S. mitis and S. mutans have
been most widely studied, since these species are also considered to display
most pathogenic potential. This far, the complete genomes of two S. mitis
strains have been sequenced. The first of them was a commensal strain S. mitis
B6 (Denapaite et al. 2010) and the second a clinical S. mitis strain SVGS_061,
isolated  from  the  blood  culture  of  a  patient  who  had  developed  a  VSSS
(Petrosyan et al. 2016).
The analysis  of  the genomes of S. pneumoniae and S. mitis has revealed
that these close relatives also share most of the virulence factors known to
contribute to the pathogenicity of S. pneumoniae (Johnston et al. 2010,
Mitchell 2011). In their analysis of the genome of S. mitis B6, Denapaite et al.
(2010) found that S. mitis B6  shared  with S. pneumoniae especially most
virulence factors involved in colonization and adherence, suggesting these
genes would be needed also for a commensal lifestyle typical for S. mitis. Most
of  the regulatory proteins involved in virulence in S. pneumoniae were also
found in the S. mitis B6 genome. Denapaite et al. (2010) concluded that the
only essential pneumococcal virulence genes that were absent in S. mitis B6
were pneumolysin ply, the choline-binding proteins pspA, pspC, pcpA, and the
hyaluronidase hlyA in addition to the genes involved in the synthesis  of  the
polysaccharide capsule.
Mitchell  (2011)  proposes  that  the  absence  of  the  polysaccharide  capsule
might be the essential factor impairing the pathogenicity of S. mitis, since the
lack of the capsule would render S. mitis vulnerable to attacks by neutrophils.
However, many other S. mitis strains have been found to contain capsule loci
(Kilian et al. 2008, Johnston et al. 2010, Petrosyan et al.  2016),  as  well  as
genes encoding pneumolysin (Whatmore et al. 2000, Neeleman et al. 2004,
Johnston et al. 2010, Kilian et al. 2014, Morales et al. 2015) and hyaluronidase
(Johnston et al. 2010).
Several choline-binding proteins were also detected in many S. mitis
strains by Kilian et al. (2014), although the genes for certain choline-binding
proteins known to be involved in attachment to host cells in S. pneumoniae,
such as PspA, were not found, in line with previous studies (Hakenbeck et al.
2009, Denapaite et al. 2010, Johnston et al. 2010). Recently, Skov Sørensen
et al. (2016) explored the expression of polysaccharide capsule genes in several
VGS species, finding that the genes involved in capsule polysaccharide
synthesis were expressed in all the VGS strains they studied. In addition to the
lack of some crucial pneumococcal virulence factor genes in S. mitis,  part of
the explanation for the lesser pathogenic potential of S. mitis might be the fact
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that many regions of the S. mitis genome are inverted in respect to the
replication  of  origin  compared  to S. pneumoniae, presumably affecting the
temporal expression patterns of these genes (Denapaite et al. 2010, Mitchell
2011).
In addition to the specific virulence factors, S. mitis has a high competence
for genetic transformation (Denapaite et al. 2010, Mitchell et al. 2010), which
presumably helps to generate the antigenic variation necessary for the evasion
of the activity of the strain-specific secretory immunoglobulin A against S.
mitis found in the human saliva (Kirchherr et al. 2005, Kirchherr et al. 2007,
Johnsborg et al. 2008). In addition of the genes involved in competence and
transformation, Denapaite et al. (2010) found in the S. mitis B6 genome genes
for bacteriocins facilitating access to foreign DNA by killing and lysing other
bacteria. On the other hand, Killian et al. (2008) found out that many S. mitis
strains  lacked  some  of  the  22  genes  that  are  considered  essential  for
competence for genetic transformation in pneumococci. In contrast, all those
22  genes  were  found  in  all  the S. pneumoniae and S. pseudopneumoniae
strains they studied.
Apart from S. mitis, the most widely studied member of the S. mitis group
is S. pseudopneumoniae. Shahinas et al.  published  in  2011  the  first  whole-
genome sequence of S. pseudopneumoniae. In 2013 Shahinas et al. published
a wider comparative analysis of the S. pseudopneumoniae. In this 2013 study
they found that S. pseudopneumoniae shared many virulence genes with S.
pneumoniae, including the genes encoding for pneumolysin (Ply) and
autolysin  (LytA).   However,  similarly  to  the S. mitis strains studied by
Denapaite et al. (2010), Johnson et al. (2010) and Kilian et al. (2014), S.
pseudopneumoniae was lacking the genes for choline-binding proteins PspA,
PspC and PcpA, which in S. pneumoniae are important cell-surface proteins
crucial for the attachment to the host cells. On the other hand, S.
pseudopneumoniae was found to have a wide array of other choline-binding
genes, which are believed to be involved in the murine synthesis and cell
separation (Shahinas et al. 2013). The variety of choline-binding proteins in S.
pneumoniae and in other MGS have been studied by Hakenbeck et al. (2009),
who  found  them  to  be  highly  polymorphic  and  to  have  undergone  several
duplications and recombination events in the course of the evolution of these
species.
In addition to the above-mentioned virulence factors, Bek-Thomsen et al.
(2012) have recently studied the evolution of zinc metalloproteases in VGS and
S. pneumoniae. Morales et al.  (2015)  have  investigated  the  gene  for
pneumococcal autolysin (lytA) in S. pneumoniae and  other  Mitis  group
streptococci and come to the conclusion that the lytA and plyA (pneumolysin)
genes tend to occur together in the same genomic islands and have recognised
eight different types of these lytA-plyA genomic islands in S. pneumoniae and
in several other Mitis group species. The close association of lytA and plyA is
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not  surprising  considering  the  autolysin  is  essential  for  the  release  of
pneumolysin from the pneumococcal cells (Mitchell et al. 2003) during
autolysis, although newer research has shown, that pneumolysin can also be
released during the growth, without the involvement of autolysin (Mitchell
and Mitchell 2010).
Of the other virulence factors,  the role of  hydrogen peroxide and NADH
oxidase in both S. pneumoniae and in other S. mitis group streptococci has
been most widely studied. Auzat et al. (1999) found that the competence for
genetic exchange or virulence could be modulated by oxygen via the oxygen-
sensing NADH oxidase. Recently, Ge et al. (2016) discovered that S. sanguinis
mutants  lacking  the  NADH  oxidase  gene  (nox) had higher intracellular
hydrogen peroxide (H2O2) and were more susceptible to environmental stress
and  reduced  survival  in  serum,  resulting  in  impaired  competitivity  and  an
impaired ability to cause endocarditis in rabbits.
Duane et al. (1993) found that all the S. pneumoniae strains they studied
produced hydrogen peroxide which was toxic to the rat alveolar epithelial cells.
Okahashi et al. (2016) also found that hydrogen peroxide (H2O2) produced by
S. oralis was able to kill human monocytes and epithelial cells. However, in a
study by Zahlten et al.  (2015)  it  was  discovered  that  the  oxidative  stress
induced  by  pneumococcal  infection  in  mouse  and  human  lung  tissue  was
independent of H2O2 and pneumolysin produced by S. pneumoniae and
instead depended on the pneumococcal autolysin LytA.
Of the other VGS species, the virulence factors of S. mutans have attracted
most scientific interest. In contrast to the S. mitis group streptococci, S.
mutans doesn’t  seem  to  share  many  virulence  factors  with S. pneumoniae.
(Krzysciak et al. 2014). The most important pathogenicity determinant it
shares with S. pneumoniae are the genes for fibrinogen-binding PavA-like
(pneumococcal adhesion and virulence A) protein and for SloC belonging to
the lipoprotein receptor antigen family (Mitchell 2003). The operon in which
sloC is contained within S. mutans is  similar  to S. pneumoniae operons
psaBCAD and adcCBA involved in the transport of divalent cations, such as
iron and manganese (Dintilhac et al. 1997, O’Rourke et al.  2010).  The  Psa
operon has been shown to be important for pneumococcal virulence (Marra et
al. 2002). Kitten et al. (2000) showed that the S. mutans strains deficient in
sloC could still cause dental caries but their ability to cause endocarditis was
reduced in a rat model. In addition to these virulence factors shared with S.
pneumoniae, S. mutans also have other pathogenicity determinants important
for attachment and biofilm formation, such as glucosyltransferases and
glucan-binding proteins (Krzysciak et al. 2014).
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2.5 PHYLOGENY OF STREPTOCOCCUS PNEUMONIAE
AND VIRIDANS GROUP STREPTOCOCCI
The parallel evolution of S. pneumoniae and other species in the viridans
group has been puzzling the scientists for decades, since early observers
already recognised that the species distinctions within these species were far
from clear-cut (Sherman et al.  1943)  and  yet  the  pathogenic  potential  of S.
pneumoniae and  other  members  of  the S. mitis group differs immensely.
Thanks  to  the  development  of  more  efficient  methods  for  nucleic  acid
amplification and sequencing within the last 25 years, researchers have been
able  to  gain  significant  new  insights  into  the  phylogeny  of  this  intriguing
bacterial  group  which  contains  both  one  of  the  most  important  bacterial
pathogens as well as integral members of healthy oral microbiota.
In  a  ground-breaking  study  published  in  1995,  Kawamura et al.
constructed the first comprehensive phylogenetic tree based on 16S rRNA
including  all  the  VGS  species  then  recognised.  The  results  of  their  study
supported  the  division  of  VGS  into  five  groups: anginosus, bovis, mitis,
mutans and salivarius.  They  also  found  that  within  the S. mitis group, S.
sanguis and S. parasanguis (later re-named as S. sanguinis and S.
parasanguinis)  were  more  closely  related  to  each  other  than  to  other
streptococci within the S. mitis group and that S. pneumoniae, S. mitis, and to
a lesser degree, S. oralis were closely related, exhibiting sequence homology of
over  99%  to  each  other.  However,  the  level  of  DNA-DNA  hybridization
between these three species was found to be significantly lower, under 60 %,
well below the traditional species separation threshold value of 70 % (Wayne
et al. 1987). This striking difference between the conservation of the 16S rRNA
gene and more diverse total DNA within these three species demanded an
explanation.
Because the highly conserved 16S rRNA sequences did not provide for an
optimal tool for the species level identification of the species within the S. mitis
group, different housekeeping genes were selected by researchers to be used
in combination in a multi-locus sequence typing approach for identification of
these species (Kawamura et al. 1999, Whatmore et al. 2000, Hoshino et al.
2005, Kilian et al.  2008,  Do et al. 2009, Rasmussen et al. 2016). The
publishing of the whole genome sequences of several S. pneumoniae (Hoskins
et al. 2001, Tettelin et al. 2001, Lanie et al. 2007, Donati et al. 2010) strains
as well as S. pseudopneumoniae strain IS 7493 (Shahinas et al. 2011, 2013)
and S. mitis strains B6 (Denapaite et al. 2007) and SVGS_061 (Petrosyan et
al.  2016) also provided more insights into the evolutionary history of  the S.
mitis group.
Comparing the partial sequences of the housekeeping genes ddl, gdh, rpoB
and sodA of  both  pneumococcal  and  non-pneumococcal  members  of  the S.
mitis strain, Kilian et al. (2008) constructed a phylogenetic tree of the S. mitis
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group. In this tree, S. infantis and S. oralis strains were both clustered
separately from the S. mitis, S. pseudopneumoniae and S. pneumoniae
strains,  which  were  clustered  significantly  closer  to  each  other  than  to  the
other members of the group. However, the strains within these three species
were also found to display remarkable polymorphism in these genes: nearly all
S. pseudopneumoniae and S. mitis strains  had  their  own  unique  alleles  of
these genes, whereas shared alleles were found almost exclusively among the
pneumococcal strains. S. pneumoniae strains were thus grouped much more
closely together in this tree than the more diverse S. mitis and S.
pseudopneumoniae strains. When performing DNA-DNA hybridization
between different S. mitis strains the researchers discovered that among the
S. mitis strains, most isolates had hybridization values well below 70 %, thus
constituting separate species following the traditional taxonomical criteria
(Wayne et al.  1987).  Designating  most S. mitis strains as separate species
would naturally be highly impractical, and the strains have therefore remained
within the S. mitis species. Kilian et al. (2008) hypothesized that the genetic
differences between individual lineages of S. mitis might result from their
sexual separation resulting from mostly vertical transfer from parents to
offspring. However, both adults and infants are found to be colonized with
numerous, highly variant, S. mitis clones  at  different  sites  on  the
oropharyngeal surfaces (Hohwy et al. 2001, Kirchherr et al. 2005) and few of
these clones seem to persist  for  more than a few weeks (Fitzsimmons et al.
1996, Hohwy et al. 2001, Kirchherr et al. 2005). In addition to that, the infants
and their mothers seem to only infrequently share the same clones (Kirchherr
et al.  2005).  These  findings  seem  to  suggest  that  the  sexual  isolation
hypothesis is inadequate in trying to explain the diversity within this species.
The homological recombination plays an important role in creating the
genetic landscape within the VGS. Extensive genetic transfer has been
reported to occur both within species and between species in S. anginosus and
S. mitis groups,  but  in  the  study  conducted  by  Hoshino et al. (2005),
recombination  was  only  found  between  the  strains  belonging  to  the  same
phylogenetic cluster (for example, between S. gordonii and S. sanguinis and
between S. anginosus and S. intermedius). This finding is not surprising in the
light of the fact that efficient recombination requires a certain degree of
sequence similarity between the strains involved (Lawrence 2002). Kilian et
al. (2008) also found several strains grouped as S. oralis on the basis of the
housekeeping genes and DNA-DNA hybridization to contain copies of the 16S
rRNA gene typical for both S. mitis and S. oralis, suggesting gene transfer from
S. mitis to S. oralis. As described in more detail in the section on the virulence
genes, both S. pneumoniae and  other  MGS  species  are  competent  for
transformation (Håvarstein et al. 1996, Pestova et al. 1996, Morrison et al.
1997, Kilian et al. 2008, Whatmore et al. 1999, Denapaite et al. 2010).
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Combining  the  analysis  of  both  16S  rRNA  gene  sequences,  MLST  using
housekeeping genes and DNA-DNA hybridization, Kilian et al. (2008) came
to  the  conclusion  that  commensal S. mitis lineages had developed from
pathogenic ancestors resembling current S. pneumoniae strains through loss
of virulence genes among other parts of the genome after a previous
evolutionary split between the mitis-pneumoniae-pseudopneumoniae and
other species in the S. mitis group such as S. oralis and S. infantis. They also
proposed that the split between pathogenic S. pneumoniae and commensal S.
mitis occurred concurrently with the development of the immunoglobulin A
(IgA) subclass in the common ancestor of humans, chimpanzees and gorillas,
about 6 to 7 million years ago (Kawamura et al. 1992). This is supported by the
fact that S. mitis has not been isolated from other primates or other mammal
groups and that S. pneumoniae  has  been  found  to  cause  infections  in
chimpanzees (Chi et al. 2007 (2), Denapaite and Hakenbeck 2011). In another
study, Kilian et al. (2014) suggest that continuous unidirectional gene transfer
from S. mitis lineages to S. pneumoniae has been helping S. pneumoniae to
evade  the  human  immune  system  by  ensuring  the  structural  variety  of  the
capsular  polysaccharides  by  importing  fragments  of  the cps operon from S.
mitis and other VGS members of oropharyngeal microbiota. This theory has
recently been corroborated by findings of Skov Sørensen et al.  (2016) when
they studied the expression of  capsular polysaccharide across different VGS
species.
S. pseudopneumoniae was  first  described  by  Arbique et al. in 2004
comprising some of the strains that historically would have been described as
”atypical pneumococci”. S. pseudopneumoniae has in several phylogenetic
studies been found to inhabit an intermediary position between S.
pneumoniae and S. mitis (Kilian et al. 2008, 2014, Rolo et al. 2013) In their
analysis of the genome sequence of S. pseudopneumoniae strain IS7493,
Shahinas et al. (2013) found that the genome of S. pseudopneumoniae IS7493
resembled that of S. pneumoniae R6 but that there was evidence of several
genetic recombinations having taken place in IS7493. Rolo et al. (2013) also
discovered signs of extensive recombination with both S. pneumoniae and S.
mitis in their analysis of the genetics of several S. pseudopneumoniae strains.
Do et al. (2009) found the population structure of S. oralis to resemble that of
S. mitis with highly variant individual lineages and evidence of significant
inter- and intraspecies recombination.
A genetic landscape like that of the MGS has been revealed for other oral
VGS, such as members of S. salivarius group (Delorme et al. 2007, 2015) and
S. mutans (Nakano et al. 2007).  These  oral  streptococci  also  seem  to  be
genetically diverse and to show wide-spread genetic recombination.
Interestingly, S. thermophilus, a member of S. salivarius group inhabiting the
mammary  mucosa  of  cows  and  used  commercially  in  dairy  industry  for
fermenting yoghurt, seems to have recently evolved from human oral species
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S. vestibularis (Pombert et al.  2009)  and  displays  far  less  genetic  variation
than  the  members  of  this  group  inhabiting  the  human  oral  mucosa.  When
looking at S. mutans,  when compared to MGS, individual  seem to carry far
fewer clones that are frequently transmitted to infants from parents and other
family members (Momeni et al. 2016).
2.6 IDENTIFICATION METHODS
2.6.1 BIOCHEMICAL IDENTIFICATION METHODS
The identification of S. pneumoniae and VGS in clinical microbiology
laboratory has been based on colony and microscopic morphology combined
with various biochemical tests. Both S. pneumoniae and  many  VGS  form
alpha-haemolytic colonies on sheep blood agar, whereas many VGS display no
haemolysis and members of the S. anginosus group of VGS often grow as very
small beta-haemolytic colonies. Many S. pneumoniae strains require
incubation in 5 % CO2, and the growth of many VGS isolates is also enhanced
in the presence of elevated level of CO2. (Spellerberg and Brandt 2011). VGS
typically  grow as chain of  cocci,  but S. pneumoniae is  often also growing as
pairs of elongated cocci. Some species may also grow as short rods in certain
conditions,  such  as S. mutans grown  in  acidic  conditions  (Spellerberg  and
Brandt  2011)  and  members  of S. anginosus group  incubated  in  5  %  CO2
(author’s unpublished experience).
For differentiating between S. pneumoniae and closely related VGS, testing
optochin sensitivity and bile solubility have been considered essential
(Spellerberg and Brandt 2011). S. pneumoniae strains are typically optochin
sensitive  and  bile-soluble,  in  contrast  to  other  VGS,  which  are  typically
optochin  resistant  and  insoluble  to  bile.  Wessels  and  co-workers  (2012)
reported that  optochin testing in a CO2-atmosphere and tube bile  solubility
testing give consistent results for S. pneumoniae. However, in another study
(Ikryannikova et al. 2011) 21 optochin susceptible isolates were identified as
S. mitis by  MLST.  Commercial  biochemical  test  panels  have  limitations  in
identifying streptococci to species level (Bascomb and Manafi 1998,
Summanen et al. 2009, Chatzigeorgieau et al. 2011, Teles et al. 2011).
2.6.2 PNEUMOCOCCAL SEROTYPING
Over 90 different capsular serotypes of S. pneumoniae have been identified
this far (Habib et al. 2017). The detection of pneumococcal serotypes is
important for monitoring the epidemiology of pneumococcal infections.
During  the  2000s,  it  has  also  become  central  to  monitoring  serotype
replacement in response to pneumococcal vaccinations (Weinberger et al.
2011). In Finland, clinical microbiology laboratories are obliged to submit all
pneumococcal  strains  isolated  from  blood  and  cerebrospinal  fluid  to  the
National Institute of Health and Welfare for serotyping
(https://thl.fi/fi/web/infektiotaudit/laboratoriotoiminta/laboratoriotutkimu
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kset, referred 29.3.2019). Quellung reaction, first described by Fred Neufeld
in 1902, is considered a golden standard of pneumococcal serotyping.
Nowadays, multiplex-PCR is also applied to pneumococcal serotyping. The use
of MALDI-TOF mass spectrometry for serotyping has also been investigated,
but this far it has not been shown to be a reliable tool for serotyping, because
different serotypes have not been shown to reproducibly display typical peaks
(Ercibengoa et al. 2019).
2.6.3 MALDI-TOF MASS SPECTROMETRY
In mass spectrometry, chemicals are ionized by various methods, such as
directing laser beams on the sample or spraying it with electrons. The mass-
charge ratio of the various components of the sample is then plotted as a mass
spectrum, showing the relative proportions of these components in the sample
in addition to the masses of  each component.  Mass spectrometry has many
applications in physics, chemistry and life sciences and can be applied to such
varied uses as enrichment of uranium for nuclear technology applications and
analysing protein composition of biological samples. Different methods have
been  developed  for  ionization  and  for  separation  of  the  ionized  sample
components  according  to  their  mass-charge  ratios.  Different  mass
spectrometry methods can also be combined in tandem mass spectrometry.
Mass spectrometry can also be used together with such chemical separation
methods as gas or liquid chromatography.
The first modern mass spectrometers were used for discovery and
identification of the different isotopes of chemical elements by Francis William
Aston in 1919. During the World War II, a type of sector mass spectrometer
called  calutron  was  used  by  Ernest  O.  Lawrence  to  separate  the  isotopes  of
Uranium, enabling the development of nuclear weapons in Manhattan project
(Parkins 2005). However, these types of mass spectrometers were not suitable
for analysis of the chemical composition of biological materials. The study of
large biological chemical compounds, such as proteins, would have required
softer ionization methods in order to maintain sufficient integrity of the
molecules.
The analysis of biological macromolecules by mass spectrometry only
became possible by development of Matrix-assisted laser
desorption/ionization mass spectrometry (MALDI) during the 1980s by Karas
et al. (1985, 1987) and Koichi Tanaka (Tanaka et al. 1988).  MALDI-TOF mass
spectrometry  utilizes  ionization  technique  in  which  pulsed  laser  beams  are
used  to  softly  ionize  large  molecules  such  as  proteins  or  peptides,  allowing
them to maintain their integrity during ionization. Before ionization, the
sample  is  injected  on  a  target  plate  and  overlaid  with  a  matrix  solution
containing organic acid such as α-cyano-4-hydroxycinnamic acid (HCCA) or
2,5-dihydroxybenzoic acid and a counter acid such as trifluoroacetic acid
(TFA)  dissolved  in  a  mixture  of  an  organic  solvent  such  as  acetonitrile  and
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deionised water. The solvents are then left to evaporate, leaving the sample
covered  in  recrystallized  matrix.  The  matrix  is  used  to  protect  the  sample
molecules during the ionization.
After being ionized by the pulsed laser, the ionized molecules are then
launched  on  a  flight  path  and  their  flight  time  measured  by  a  detector  in  a
process called time-of-flight (TOF).  The measured flight time of  the ionized
molecules is then used to calculate their mass-charge ratio and create a mass
spectrum showing the relative abundance of molecules of various masses
contained in the sample. Time-of-flight mass spectrometry is useful in analysis
of biological molecules because it allows for detection of molecules over a wide
mass range.  In case of  microbial  identification,  the mass range measured is
typically between 2 000 and 20 000 Da.
Within the last ten years the matrix-assisted laser desorption/ionization-
time of flight mass spectrometry (MALDI-TOF MS) has established itself as a
fast and cost-effective identification method for a wide range of microbes, both
bacteria and fungi. (Seng et al. 2009, Bizzini et al. 2010, Neville et al. 2011,
Martin et al. 2017). Although Anhalt and Fenselau had investigated the use of
mass  spectrometry  for  bacterial  identification  already  in  1975,  mass
spectrometry for microbial identification wasn’t widely studied before the late
1990s  and  early  2000s  when  new  MALDI-TOF  technology  enabled  more
gentle treatment of microbial cells (Claydon et al. 1996, Krishnamurty et al.
1996, Fenselau and Demirev 2001). Earlier mass spectrometry methods had
disintegrated the microbial proteins into peptides, thus yielding them
unsuitable for identification purposes. With the MALDI-TOF technology, the
bacterial  proteins  are  better  conserved,  allowing  for  identication  based  on
comparison of signature of protein spectra typical for different species
(Fenselau  and  Demirev  2001).  The  mass  range  detected  for  microbiological
applications is typically between 2 000 and 20 000 Da. An example of MALDI-
TOF mass spectrum for a bacterial strain is shown in figure 2.
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Figure 2.  An example of a MALDI-TOF mass spectrum of a bacterial strain
For microbial identification, the protein spectra need to be compared to a
database composed of protein spectra of well-characterised reference strains
by a dedicated software utilising an algorithm which calculates the similarity
of the sample spectra to the reference spectra of the database. This similarity
is  then  expressed  in  a  numerical  form,  as  percentage  on  the  VITEK  MS
platform (BioMérieux) and as a score value ranging from zero to three in the
MALDI  Biotyper  system  (Bruker  Daltonics).   The  standard  log(score)
algorithm  employed  by  MALDI  Biotyper  gives  the  same  relative  weight  to
similarity across the whole mass range of 2 000-20 000 Da. In contrast, the
algorithm  employed  in  VITEK  MS  weighs  specific  peaks  in  the  mass  areas
showing particularly high variability when calculating the identification
results (Rychert et al. 2013).
Within  the  last  decade  MALDI-TOF mass  spectrometry  has  been  widely
studied and adopted in clinical microbiology laboratories for identification of
pathogenic bacteria (Seng et al. 2009, Bizzini et al. 2010, Neville et al. 2011).
In contrast to nucleic acid amplification tests (NAATs), identification by
MALDI-TOF mass spectrometry is usually performed on microbial biomass
extracted  from  a  culture  medium,  such  as  culture  plates  or  blood  culture
bottles.  The  main  benefits  of  MALDI-TOF  mass  spectrometry  compared  to
traditional biochemical methods include its quick time to identification
(minutes compared to hours to days when using biochemical methods), low
reagent costs and specificity (Martin et al. 2017, Ródriguez-Sánchez et al.
2019).  MALDI-TOF  mass  spectrometry  also  has  lower  reagents  costs  than
NAATs. Neville et al. (2011) estimated the cost of MALDI-TOF identification
to  be  only  0.45  Australian  dollars  (roughly  0.70  €)  per  isolate,  which  is
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significantly less than typical costs of NAATs, which typically cost 10-100
hundred times more per isolate.
Another  benefit  of  MALDI-TOF  mass  spectrometry  in  comparison  to
NAATs is that it can be used to identify any bacteria or fungi included in the
database of the instrument, unlike NAATs that target a specific gene or a set
of  genes  for  detection  of  a  limited  number  of  organisms  at  time.  Since  the
databases of the MALDI-TOF instruments today include spectra from
thousands of bacterial species, MALDI-TOF mass spectrometry can be used to
reliably identify almost any bacterium isolated in a clinical microbiology
laboratory, greatly decreasing the need for several separate identification tests
for different group of bacteria (Martin et al. 2017).
On  the  other  hand,  the  technical  limitations  of  MALDI-TOF  for  use  in
microbiology include the fact that enrichment by culture methods is typically
required in order to generate enough bacterial biomass for identification and
its difficulty in identifying several bacteria from mixed cultures. MALDI-TOF
mass spectrometry also cannot reliably distinguish between certain very
closely related bacterial species such as Escherichia coli and Shigella sp. or the
different species of Mitis group streptococci. It is interesting to note, that the
species that are difficult to differentiate by MALDI-TOF are typically also
difficult to reliably identify to species level using 16S rRNA sequencing, which
is generally considered a golden standard in bacterial identification.
MALDI-TOF mass spectrometry has also been successfully applied to
identification  of  other  clinically  relevant  microbial  groups,  such  as
mycobacteria, yeasts and filamentous fungi (Martin et al. 2017). The
extraction of bacterial biomass for MALDI-TOF identification from certain
bacterial  groups  containing  mycolic  acid  in  their  cell  walls,  such  as
mycobacteria and aerobic actinobacteria like Nocardia and Streptomyces, has
proved challenging (Martin et al. 2017, Rodríguez-Sánchez et al. 2019).
Another  drawback  is  the  inability  of  MALDI-TOF  to  distinguish  between
different species of the Mycobacterium tuberculosis complex. However, the
development of modified glass bead extraction methods and introduction of
identification modules specifically designed for identification of mycobacteria
have allowed for reliable identification of atypical mycobacteria (Rodríguez-
Sánchez et al. 2016, Alcaide et al. 2018). When it comes to the MALDI-TOF
identification of clinically relevant fungi, yeast species can be identified
utilising  the  standard  sample  processing  protocols  (Chao et al. 2014). In
contrast, MALDI-TOF identification of filamentous fungi such as moulds and
dermatophytes  often  requires  prior  incubation  in  an  enrichment  broth  in
order to produce more homogenic mycelia (Cassagne et al. 2016).
For  diagnosis  of  bacteraemia,  enrichment  of  blood  specimens  in  an
automated blood culture system is still necessary, but the time to identification
of microbes growing in positive blood culture has been significantly reduced
in recent years by adoption of rapid identification methods such as automated
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real-time PCR and isothermal amplification assays and MALDI-TOF mass
spectrometry. Whereas identification of microbes growing in a blood culture
bottle using traditional biochemical methods would typically take 1 to 2 days
in the case of aerobic bacteria and 4 to 7 days for anaerobic bacteria (Tabak et
al. 2018), performing NAAT or MALDI-TOF identification directly from a
positive blood culture can reduce this time to 30 to 120 minutes (Ferreira et
al. 2011, Kok et al. 2011, Dixon et al. 2015). This has been showed in studied
by Martiny et al. (2013) and Clerc et al. (2013) to allow for earlier initiation of
targeted antibiotic treatment. In a study carried out by Clerc et al. (2013) early
MALDI-TOF identification directly from positive blood culture bottle led to
the adjustment of antibiotic treatment in 35 % of the bacteraemia cases. In the
same  study  it  was  also  noticed,  that  these  changes  in  antibiotic  treatment
typically led to a switch to a narrower-spectrum antibiotic, significantly
reducing  the  use  of  carbapenems  and  other  broad-spectrum  antibiotics.
Limiting the unnecessary use of broad-spectrum antibiotics is in turn
important for combating the spread of antibiotic resistance, since exposure to
these antibiotics selects for strains harbouring genes coding for resistance to
them. Dixon et al. (2015) also found that MALDI-TOF identification of
bacteria  isolated  from  blood-stream  infection  resulted  in  a  reduction  of
subsequent length of stay and treatment costs. A rapid identification of
potential contaminants is also important, in many cases preventing the
starting of unnecessary antibiotic treatment (Martiny et al. 2013).  Thus, it is
important to develop these techniques so that all significant pathogens could
be  identified  directly  from  positive  blood  culture  bottles  using  these
techniques.
Identification of Streptococcus pneumoniae and VGS by MALDI-TOF MS
has been widely studied (van Veen et al. 2010, de Bel et al. 2010, Neville et al.
2011, Scholz et al. 2012, Martiny et al. 2012, Werno et al. 2012, Davies et al.
2012, Lopez Roa et al. 2013, Ikryannikova et al. 2013, Dubois et al. 2013,
Branda et al. 2013, Woods et al. 2014, Angeletti et al. 2015, Isaksson et al.
2015, Van Prehn et al. 2016). What has emerged from these studies has been
that whereas other members of VGS can be more reliably distinguished from
S. pneumoniae by MALDI-TOF, reliable differentiation between S.
pneumoniae and  other  members  of S. mitis group has proven more
challenging  because  of  the  close  relationship  of  these  species.  Within  VGS,
reliable species level identification has proved challenging, since the protein
spectra of  the species included in the same VGS subgroup (S. anginosus, S.
bovis, S. mitis, S. mutans, S. salivarius or S. sanguinis groups) typically
resemble each other, reflecting their close genetic relationship.
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2.6.4   MOLECULAR DIAGNOSTCS
Within  last  couple  of  decades,  diagnostic  assays  based  on  the  detection  of
nucleic acid sequence specific for certain pathogenic microbes have been
widely adopted in clinical microbiology laboratories. Advances in diagnostic
techniques, such as real-time PCR and isothermal amplification, have reduced
the hands-on-time required, as well time-to-results and cost of these assays,
allowing for their use also in large-scale routine diagnostic investigations. In
addition to the development of more integrated and automated nucleic acid
amplification platforms, their miniaturization has been instrumental in the
spreading  of  nucleic  acid  amplification  techniques  (NAATs).   Compared  to
immunochromatographic antigen detection tests, the nucleic acid
amplification tests have the benefit of greater sensitivity, reducing the need for
further confirmatory tests. Although NAATs target specific genes,
development of multiplex nucleic acid amplification tests has allowed for
detection of several target genes simultaneously in the same assay. This, along
with automatization and miniaturization of the nucleic acid amplification
platforms  has  greatly  enhanced  their  appeal  to  clinical  microbiology
laboratories,  enabling  the  detection  of  several  key  pathogens  from  a  single
sample.  Such  multiplex  NAAT  panels  are  typically  tailored  to  include  key
bacterial  pathogens typically  isolated from a certain specimen type,  such as
stool or cerebrospinal fluid.
The  16S  rRNA  gene,  which  is  widely  used  in  molecular  identification  of
bacteria, is highly conserved among the species within a certain group of VGS
(such as S. mutans group or S. mitis group) (Kawamura et al. 1995, 1999,
Hoshino et al.  2005) and might even be present in several variant copies in
some strains (Kilian et al. 2008), yielding it suboptimal as an identification
tool for this group of bacteria to the species level. However, Haanperä et al.
(2007) showed that pyrosequencing of the most variable part of the 16S rRNA
gene,  located  in  its  5’  end,  could  be  used  for  identification  of  VGS  to  the
subgroup  level.  Pyrosequencing,  which  is  a  rapid  and  low-cost  sequence
generation method, has also been applied for identification of streptococci
amplifying the RNase P RNAse gene, rnpB (Innings et al. 2005).    Therefore,
several other genes have been targeted in identification and phylogenetic
studies,  often  using  a  multi-locus  sequence  typing  (MLST)  approach
(Kawamura et al. 1999, Whatmore et al. 2000, Hoshino et al. 2005, Chi et al.
2007, Nakano et al. 2007, Kilian et al. 2008, Do et al. 2009, Thompson et al.
2013, Delorme et al. 2015, Rasmussen et al.  2016).  Some  of  the  most
commonly used targets include the housekeeping genes for D-alanine-D-
alanine ligase (ddl) (Garnier et al. 1997, Kawamura et al. 1999, Kilian et al.
2008), heat shock proteins chaperonin-10, GroES and chaperonin-60, GroEL
(groESL) (Teng et al.  2002),  RNA  subunit  of  endoribonuclease  B  (rnpB)
(Täpp et al. 2003, Innings 2005, Isaksson et al. 2015), the β-subunit of RNA
polymerase (rpoB) (Drancourt et al. 2004), manganese-dependent
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superoxide dismutase (sodA) (Poyart et al. 1998, Poyart et al. 2002),
elongation factor Tu (tuf) (Picard et al.  2004)  and  a  conserved  subunit  of
bacterial recombinase, recA (Zbinden et al. 2011, Sistek et al. 2012). Of these,
the recA gene is a housekeeping gene which has been selected for a candidate
gene for species differentiation between S. pneumoniae and MGS as well as
within SMG because of  its  high interspecies variation within MGS. A 756bp
fragment of recA amplified in a real-time PCR assay developed by Sistek et al.
2012 was shown to allow good differentiation between S. pneumoniae and S.
pseudopneumoniae. However, MLST is too expensive and time-consuming to
use as a  routine identification tool  in a clinical  microbiology laboratory and
therefore remain more of a research tool.
Shahinas et al. (2013), Kilian et al. (2014) and Rasmussen et al. (2016) have
explored the use of whole genome sequencing as a tool for investigating the
phylogenetic relationships among clinical strains of the MGS. These analyses
have  provided  more  insights  into  the  genomic  organisation  for  the  MGS,
corroborating the previous evidence for wide-spread genetic recombination
and providing new information especially on the presence and organisation of
virulence genes in members of SMG, as discussed previously. Recently, Zheng
et al. (2016) have published StreptoBase, an online database and collection of
information for the identification of SMG (http://streptococcus.um.edu.my).
The  strategies  based  on  MLST  and  whole  genome  sequencing  discussed
above are at least currently too expensive and cumbersome for differentiation
of Streptococcus pneumoniae and  Viridans  group  streptococci  in  a  routine
clinical microbiology laboratory. In contrast, several nucleic acid amplification
tests based on PCR and intended for detection of S. pneumoniae directly from
patient samples have therefore been developed.
In  an  early  pneumococcal  PCR  study,  Rudolph et al. (1993) amplified
pneumolysin  and  autolysin  genes  from  blood  samples,  with  a  sensitivity  of
37.5 % for whole blood samples. Zhang et al. (1995) developed a PCR test to
detect  a  part  of  the  pneumococcal  PBP  2B  gene  from  the  whole  blood  of
patients with bacteremic bacterial pneumonia, obtaining a sensitivity of 80 %.
Dagan et al. (1998), Toikka et al. (1999), Lorente et al. (2000) and Dominguez
et al. (2001) used traditional PCR and agarose gel electrophoresis to amplify
pneumococcal pneumolysin gene directly from blood samples of patients with
suspected  community-acquired  pneumonia,  but  all  of  these  reported  low
sensitivity ranging from 26.6 % (Dominguez et al. 2001) to 55 % (Lorente et
al. 2000). Salo et al. (1995) and Menendez et al. (1999) had reported improved
sensitivity of PCR test detecting fragment of pneumolysin genes when using
nested PCR from serum samples from patients with community-acquired
pneumonia  compared  to  blood  cultures,  but  considered  the  multiple  steps
required  to  process  the  blood  samples  and  extract  the  DNA  a  significant
drawback of their method. In general, the PCR assays they studied tended to
require  fractioning  the  blood  samples  and  only  show  high  sensitivity  when
36
analysing samples from patients for whom bacterial  culture from blood was
also positive.
In 2004, Sheppard et al. developed a real-time PCR assay for detection of
S. pneumoniae targeting the pneumococcal autolysin-gene, but in line with the
results  of  previous  studies,  reported  a  sensitivity  of  only  42.9  %  when
analysing EDTA blood samples from patients with blood-culture-confirmed
pneumococcal infections.  In 2009, Smith et al. compared the performance of
a PCR protocol targeting both pneumolysin and autolysin genes to Binax NOW
S. pneumoniae urinary antigen test in diagnosing pneumococcal infections in
adults with community-acquired pneumonia and found the dual-PCR assay to
be significantly less sensitive than the urine antigen detection test. Abdeldaim
et al.  (2010)  evaluated  the  performance  of  three  real-time  PCR  assays,
targeting genes for autolysin and pneumolysin as well as S. pneumoniae 9802
gene fragment (Spn9802). They reported that the assay targeting the ply gene
was too unspecific for clinical use, whereas autolysin and Spn9802 assays
showed higher specifities (100 % and 98 %, respectively), although also lower
sensitivities than pneumolysin assay.
More recently, Clancy et al. (2015) have also designed an isothermal nucleic
acid amplification assay utilizing rapid recombinase polymerase amplification
technique (RPA), targeting the pneumococcal gene encoding leader peptidase
A.  They  had  only  analysed  a  small  number  of  clinical  blood  samples  but
reported  that  the  assay  was  positive  for  8  of  the  11  blood  culture-positive
patient blood samples.  As they allow for fast nucleic acid amplification, several
other  assays  based  on  isothermal  amplification  methods  have  also  been
designed, especially for diagnosis of pneumococcal meningitis. These assays
are often incorporated into multiplex panels simultaneously targeting several
bacterial pathogens which often cause meningitis. Examples of such multiplex
assays include an assay designed by Clancy et al. (2016) utilizing nucleic acid
sequence-based amplification (NASBA) and one designed by Soysal et al.
(2017) based on line probe assay (LPA) technology.
The ABACUS GenomEra S. pneumoniae test (Abacus Diagnostica, Turku,
Finland) is an identification test based on automated nucleic acid
amplification reaction using primers specific for Streptococcus pneumoniae.
The target gene of these primers has not been disclosed by the manufacturer.
The Genomera CDX instrument automatically identifies the inserted test chips
by reading barcodes on the chips. The chips are then sealed thermally in order
to minimize the risk of cross-contamination. The nucleic acid amplification
reaction is performed by automatically transporting the test chips between
blocks heated to different temperatures for denaturing, annealing/extension
and measurement. The speed of the amplification is further enhanced by using
heat-conducting  metallic  background  for  the  test  chips  and  by  inclusion  of
extreme-temperature blocks in the thermocycling. The amplification products
are detected by homogenous fluorescence measurement using enhanced
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competitive hybridization technique (Hagren et al.  2008).  In  enhanced
competitive hybridization, two partially complementary oligonucleotide
probes bind to the target DNA more tightly than to each other, allowing for
more sensitive detection of the target DNA.  Furthermore, the use of heat-
resistant, time-resolved fluorescent lanthanide label on the label probe
effectively reduces sample autofluorescence (Hirvonen 2017). The whole assay
can  be  completed  in  50  minutes  and  up  to  four  samples  can  be  analysed
simultaneously.  In  addition  to  GenomEra  S.  pneumoniae  assay,  there  are
currently  commercially  available  GenomEra  assays  for  the  detection  of
MRSA/SA, Clostridium difficile, Streptococcus agalactiae and norovirus.
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3  AIMS OF THE STUDY
The general aim of this work was to investigate whether MALDI-TOF mass
spectrometry and nucleic acid amplification methods could be used to enable
the rapid and reliable identification of Streptococcus pneumoniae and
differentiation between S. pneumoniae and  mitis  group  streptococci  in  a
clinical microbiology laboratory.
The specific aims were:
I  To  compare  the  performance  of  two  MALDI-TOF  systems,  MALDI
Biotyper and VITEK MS for identification of Streptococcus pneumoniae and
viridans group streptococci.
II To investigate whether the performance of MALDI Biotyper system for
differentiation between S. pneumoniae and mitis group streptococci could be
enhanced by the combined addition of more strains into the MALDI Biotyper
database and the incorporation of novel result interpretation algorithm.
III To investigate the performance of ABACUS GenomEra S. pneumoniae
nucleic acid amplification test for direct detection of Streptococcus
pneumoniae directly from positive blood culture bottles.
39
4   MATERIALS AND METHODS
4.1 BACTERIAL STRAINS AND CULTURE METHODS
4.1.1 BACTERIAL STRAINS
Both reference streptococcal strains and Streptococcus pneumoniae and
Viridans group streptococcal strains isolated from patients with invasive
streptococcal infections at the Clinical Microbiology Department of Turku
University Hospital were utilised in this study. The strains and sample
materials  used  in  this  study  are  listed  in  original  publications  (I-III)  and
summarized in the figure 3.
Figure 3. A schematic diagram of the strains and specimens used in the different publications
included in this study. N = Number of strains or specimens, GPC = gram-positive cocci, VGS =
Viridans group streptococci, MGS = Mitis group streptococci.
For the first part of this study, the performance of MALDI Biotyper (Bruker
Daltonics, Bremen, Germany) and VITEK MS (bioMérieux, Marcy-l’Etoile,
France) MALDI-TOF mass spectrometry systems for identification of Viridans
group streptococci was compared. This comparison was performed by
identifying  a  collection  of  54  streptococcal  reference  strains  and  97  clinical
Viridans group streptococcal strains isolated from positive blood cultures on
both MALDI-TOF systems. The 16S rRNA gene of these clinical Viridans group
streptococcal strains had previously been partially sequenced using
pyrosequencing as described in Haanperä et al. 2007.
40
In the second part of this study, comparing the performance of different
MALDI  Biotyper  database  versions  and  identification  algorithms  in
differentiation of S. pneumoniae and Mitis group streptococci, 111 MGS strains
isolated from invasive infections (60 of which had also been included in the
earlier  parts  of  this  study)  were  analysed  (II,  figure  3).  The S. mitis/S.
sanguinis group strains had been preliminarily  identified as belonging to S.
mitis or S. sanguinis groups by biochemical identification by VITEK2
instrument  (BioMérieux,  Marcy-l’Etoile,  France)  and  confirmed  as  such  by
partial  sequencing  of  the  16S  rRNA  gene.  A  collection  of  188  serotyped S.
pneumoniae strains isolated from blood culture specimens, 37 of which had
also been included in the second part of this study, was also included.
In order to evaluate the ability of the automated PCR assay GenomEra S.
pneumoniae (Abacus Diagnostica, Turku, Finland) to differentiate between S.
pneumoniae  and  closely  related  other  Mitis  group  streptococci,  53  clinical
MGS strains (44 S. mitis group streptococcal strains and 9 S. sanguinis group
strains)  that  had  been  included  in  the  first  part  of  this  study,  were  also
included  in  the  third  part  of  this  study  (III,  figure  3).  A  collection  of  37
serotyped S. pneumoniae strains isolated from positive blood cultures at the
Clinical Microbiology Laboratory of Turku University Hospital and a collection
of positive blood culture specimens isolated at FIMLAB laboratories was also
included in the third part of this study.
4.1.2 CULTURE CONDITIONS
For MALDI-TOF identification (I-III), streptococcal strains were stored in
a mixture of skimmed milk and glycerol at -70°C and subsequently cultured
on BD BBL™ Trypticase™ Soy Agar with 5 % Sheep Blood (Becton Dickinson,
Franklin Lakes, New Jersey, USA). After incubation at 35°C with 5 % CO2 for
17-24 h, the strains were re-inoculated from these initial culture plates on BD
BBL™  Trypticase™  Soy  Agar  with  5  %  Sheep  Blood  (Becton  Dickinson,
Franklin Lakes, New Jersey, USA). The resulting pure cultures were incubated
at  35°C  with  5  %  CO2 for  17-24  h  before  analysis  with  MALDI-TOF  mass
spectrometry.
For evaluation of identification of S. pneumoniae with  automated  PCR
assay GenomEra S. pneumoniae (Abacus Diagnostica, Turku, Finland) (III),
the streptococcal strains isolated at the Clinical Microbiology Department of
Turku University Hospital were stored and incubated at Clinical Microbiology
Laboratory of Turku University Hospital as described above. The strains were
then re-inoculated from these initial culture plates on sheep blood agar (LabM
Ltd, Heywood, Lancashire, UK) and incubated at 37°C with 5 % CO2 for 18 h
at FIMLAB Laboratories.
Positive blood culture specimens yielding gram-positive diplococci or
gram-positive  cocci  growing  in  chain  formations  were  also  collected  at
FIMLAB Laboratories for evaluation of identification of S. pneumoniae with
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automated PCR assay GenomEra S. pneumoniae (Abacus Diagnostica, Turku,
Finland)  (III).  These  blood  culture  specimens  had  been  incubated  on
BacT/Alert automated blood culturing system (bioMérieux, Marcy l’Etoile,
France). For comparative identification methods (Vitek MS, bioMérieux and
StrepID 32, BioMérieux), these positive blood culture specimens were also
subcultured on blood and chocolate agars (LabM Ltd) and fastidious anaerobe
agar (LabM Ltd).
4.2 METHODS USED IN THIS STUDY
The methods used in this study are summed in table 1.
Table 1. Summary of the methods and instruments used
4.2.1 BIOCHEMICAL IDENTIFICATION METHODS
The S. pneumoniae strains used in this study had been identified as
pneumococci by optochin sensitivity testing using optochin discs (Optochin 10
μg, DIATABS™, ROSCO Diagnostica A/S, Taastrup, Denmark). Optochin
sensitivity  testing  was  also  performed  for  all  VGS  strains  included  in  this
study.  All S. pneumoniae strains had also been serotyped and confirmed as S.
pneumoniae by optochin sensitivity and bile solubility testing at the Finnish
National Institute for Health and Welfare. All clinical streptococcal strains
used  in  this  study  had  also  been  presumptively  identified  by  an  automated
biochemical identification system (VITEK 2, BioMérieux). For the second part
of this study, the strains isolated from positive blood culture bottles were also
identified by a biochemical test panel, StrepID 32 (BioMérieux).
Publication I II III
MALDI-TOF
identification
MALDI Biotyper, VITEK
MS
MALDI
Biotyper
MALDI
Biotyper
ABACUS GenomEra
S. pneumoniae test
No No Yes
VITEK 2
identification
Yes Yes Yes
Optochin sensitivity
testing
Yes Yes Yes
Bile solubility testing
(pneumococcal
strains)
No Yes Yes
Pneumococcal
serotyping
No Yes Yes
Pyrosequencing Yes Yes Yes
recA sequencing No Yes No
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4.2.2 PNEUMOCOCCAL SEROTYPING
All S. pneumoniae strains  used  in  this  study  were  confirmed  as
pneumococci by the Finnish National Institute for Health and Welfare with a
multiplex PCR specific for S. pneumoniae as described by Siira et al. (2012).
Pneumococcal  serotyping  based  on  Quellung  reaction  had  also  been
performed at the Finnish National Institute for Health and Welfare for all
pneumococcal strains included in this study.
4.2.3 IDENTIFICATION USING MALDI-TOF MASS SPECTROMETRY
For MALDI-TOF identification using MALDI Biotyper (Bruker Daltonics,
Bremen, Germany) (I-III), the isolates were initially inoculated directly from
colonies to the steel target plates as duplicates. On top of each of these spots,
1 μl of matrix solution (α-cyano-4-hydroxycinnamic acid in 50 %
acetonitrile/2.5 % trifluoroacetic acid, Bruker Daltonics, Bremen, Germany)
was added. Bacterial Test Standard calibrant (Bruker Daltonics) was used as a
quality control on each plate. Bacterial Test Standard consists of a freeze-dried
reference strain Escherichia coli ATCC 25922 to which RNAse A and bovine
serum albumin was utilized have been added to provide coverage of higher
molecular weight range (10 000-20 000 Da) of the instrument’s measurement
area of 2 000-20 000 Da. The isolates yielding an identification score between
1.7 and 1.999 were designated as “good identification to the genus level” by the
MALDI Biotyper software. The isolates yielding a score value <1.7 were
designated as “no reliable identification”. All strains yielding identification
results with a score value under 2.0 were subsequently reanalysed using the
standard extraction protocol recommended by Bruker Daltonics.
In the extraction protocol recommended by Bruker Daltonics, bacterial
biomass was collected with 1 μl plastic loop. It was then suspended in 300 μl
chromatography-grade deionized water, to which 900 μl of absolute ethanol
was added. Repeated centrifugation (2 min, 13 000 rpm) was then performed,
with  disposal  of  supernatant  after  each  round.  The  resulting  pellet  was
suspended in 10-30 μl of 80 % formic acid, the volume of formic acid added
depending  on  the  size  of  the  pellet.  After  two  minutes’  incubation  at  room
temperature, a volume of acetonitrile equal to the volume of formic acid was
added. Finally, a centrifugation step (2 min, 13 000 rpm) was performed. We
then added 1 μl of bacterial extract on two consecutive spots on the steel target
plate.   When  the  spots  had  dried,  they  were  overlaid  with  1  μl  of  matrix
solution.
For MALDI-TOF identification using the VITEK MS instrument
(BioMérieux, Marcy l’Etoile, France) (I and III), bacterial colonies were
inoculated as duplicates on disposable target plates (BioMérieux, Marcy
l’Etoile, France) using a 1 μl plastic loop. On one of these spots, 25 % formic
acid was added as recommended by the manufacturer for identification of
yeasts.  When  spots  were  dry,  1  μl  of  the  matrix  solution  (α-cyano-4-
43
hydroxycinnamic acid (VITEK MS CHCA, BioMérieux) was added on each of
them. Escherichia coli ATCC 8739 was used as a calibrant and internal control
following manufacturer’s instructions.
If  the analysis  yielded a percent probability  match of  under 60 (the best
possible  probability  match  being  99.9),  the  isolate  was  considered  non-
identified and the same sample preparation protocol was repeated.
For this study, the MALDI-TOF identifications were performed using both
the Microflex LT instrument (Bruker Daltonics, Bremen, Germany), (figure 4)
at the Clinical Microbiology Department of Turku University Hospital (I-III)
and VITEK MS instrument (BioMérieux,  Marcy l’Etoile,  France,  figure 5)  at
the Department of Clinical Microbiology of Päijät-Häme Social and Health
Care Group in Lahti (I) and at FIMLAB laboratories in Tampere (III).
Figure 4. Microflex LT instrument, Bruker Daltonics
Figure 5. VITEK MS instrument, BioMérieux (source: BioMérieux)
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The database versions and algorithm utilised in various publications
contained in this study are outlined in Table 2.
Table 2. MALDI-TOF databases and algorithms used in this study, including the
number of S. pneumoniae, S. mitis and S. oralis reference spectra in different
database versions of MALDI Biotyper
Publication I II III
VITEK MS IVD database
version
VITEK MS IVD
database v2/
VITEK MS
SARAMIS
VITEK MS
IVD database
v2
MALDI Biotyper database
versions (strains)
3.3.1.0 (4613
strains)
3.3.1.0 (4613
strains) 4.0.0.1
(5627 strains)
3.3.1.0 (4613
strains)
The number of S.
pneumoniae reference
spectra in the MALDI
Biotyper database version
tested
8 8 (3.3.1.0)
30 (4.0.0.1)
8
The number of S. mitis
reference spectra in the
MALDI Biotyper database
version tested
1 1 (3.3.1.0))
39 (4.0.0.1)
1
The number of S. oralis
reference spectra in the
MALDI Biotyper database
version tested
4 4 (3.3.1.0)
38 (4.0.0.1)
4
Algorithm used for MALDI-
TOF identification with
MALDI Biotyper
log(score) log(score),
list(score) (used
only in
conjunction with
4.0.0.1)
log(score)
For comparison of two MALDI-TOF identification systems in the first part
of this study, the identifications were performed using both Flex Control 3.0
software and MALDI Biotyper DB Update 3.3.1.0 containing 4 613 reference
entries on Microflex LT (Bruker Daltonics, Bremen, Germany) and VITEK MS
IVD  v2  database  on  VITEK  MS  instrument  (bioMérieux,  Marcy  l’Etoile,
France). For the first part of this study, the streptococcal type strains not
adequately  identified  when  using  VITEK  MS  IVD  v2  database  were  also
subsequently  identified  with  VITEK  SARAMIS  (RUO)  database.  MALDI
Biotyper DB Update 3.3.1.0 contained reference spectra for 53 of the 54 species
included in the reference strain collection tested. In contrast, only 38 of the 54
streptococcal  species in the reference strain set  were included in the VITEK
MS IVD v2 database.
45
For  the  second  part  of  this  study,  the  clinical  pneumococcal  and
Streptococcus mitis group strains were identified by MALDI-TOF using both
the Microflex LT instrument (Bruker Daltonics, Bremen, Germany) at the
Clinical Microbiology Department of Turku University Hospital. Spectra were
analysed using MALDI Biotyper software version 3.0 (RUO) for both database
versions 3.3.1.0 containing 4 613 reference entries and 4.0.0.1 containing 5
627 reference. Of these database versions, MALDI Biotyper database version
3.3.1  (4  613  entries)  contained  1 S. mitis,  4 S. oralis and  8 S. pneumoniae
strains. The updated database version 4.0.0.1 (5 627 entries) contained 39 S.
mitis, 38 S. oralis, and 30 S. pneumoniae isolates (table 2).
For result interpretation, the standard MALDI Biotyper data interpretation
rules [using log(scores) for the best and second-best matches of the ranking
list] were applied to both database versions. Using MALDI Biotyper database
version 4.0.0.1, the first 10 positions of the ranking lists were additionally used
to calculate a new supplementary list(score) as described in the third part of
this  study  in  more  detail.  At  the  first  step,  each  log(score)  of  the  first  10
positions of a ranking list was multiplied by a factor of 10 (1st position), a factor
of 9 (2nd position), .  .  .,  a factor of 2 (9th position), and a factor of 1 for the
10th  position  to  calculate  weighted  log(scores).  In  the  second  step,  each
weighted log(score) was summarized for each single species appearing in the
ranking list. List(scores) were then compared between all species appearing in
the ranking list. Such list(scores) can be applied to differentiation of closely
related microorganisms. It naturally requires a database content of more than
10 strains per species in order to be useful.
For the third part of this study, MALDI-TOF identification of the isolates
belonging to the streptococcal collection had been performed using Flex
Control 3.0 software and MALDI Biotyper DB Update 3.3.1.0 containing 4 613
reference entries on Microflex LT (Bruker Daltonics, Bremen, Germany at the
Clinical Microbiology Department of Turku University Hospital. Conversely,
MALDI-TOF identification of the strains isolated from the positive blood
culture  bottles  was  performed  at  FIMLAB  laboratories  in  Tampere  using  a
VITEK MS IVD v2 database on VITEK MS instrument (bioMérieux).
4.2.4 ABACUS GENOMERA S. PNEUMONIAE ASSAY
For  the  third  part  of  this  study,  the  pneumococcal  nucleic  acid
amplification assays were run on GenomEra CDX (Abacus Diagnostica), which
is  a  compact  fully  automated  thermal  cycler  (figure  6),  at  FIMLAB
Laboratories at Tampere, Finland.
For the pneumococcal and S. mitis/S. sanguinis group streptococcal
culture collection strains, bacterial biomass collected from a single bacterial
colony from a pure culture plate was suspended in 1 ml of GenomEra Sample
Buffer. For the positive blood culture bottles, 25 μl of blood was diluted in 1 ml
of  GenomEra  Sample  Buffer.  35  μl  of  these  sample  suspensions  was  then
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transferred to a GenomEra S. pneumoniae test chip, which contained all the
PCR reagents and an internal amplification control.
Figure 6. ABACUS GenomEra CDX instrument
The software used for the interpretation of the nucleic acid amplification
results  from  the  GenomEra  CDX  instrument  calculates  numerical  signal
values for the target sequence, ranging from a -15 (negative) to +100 (strong
positive).  The results  that  fall  in the area between -5 and +5 are considered
inconclusive.
4.2.5 PYROSEQUENCING
All  the  Viridans  group  streptococcal  strains  used  in  this  study  were
identified  by  pyrosequencing  of  the  16S  rRNA gene  at  the  Finnish  National
Institute  for  Health  and  Welfare  as  described  by  Haanperä et al. (2007).
Sequence data from previously sequenced isolates were re-analysed for the
third  part  of  this  study  in  order  to  evaluate  whether  any  of  these  isolates
belonged to the newly described species Streptococcus dentisani (Camelo-
Castillo et al. 2014) or Streptococcus tigurinus (Zbinden et al. 2012).
4.2.6 recA GENE SEQUENCING
In the second part of this study, in addition to pyrosequencing of the 16S
rRNA gene, recA sequencing according to Sistek et al. (2012) was performed
for 24 SMG strains. The sequencing of the recA gene was performed in order
to confirm whether these isolates belonged to the species Streptococcus
pseudopneumoniae.  These strains were selected for the recA gene sequencing
because they did not fall  clearly into any specific  SMG species based on the
results of pyrosequencing of the 16S rRNA gene. In contrast, their 16S rRNA
sequences differed by the same number of nucleotides (1 to 3 nucleotides)
from  those  of  the  type  strains  of S. pneumoniae, S. pseudopneumoniae, S.
mitis, and S. oralis
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5   RESULTS
5.1 ASSESSMENT OF THE PERFORMANCE OF MALDI
BIOTYPER AND VITEK MS FOR IDENTIFICATION OF
VIRIDANS GROUP STREPTOCOCCI (I)
The results of the MALDI-TOF identifications performed in this study are
shown in Table 3.
For comparison of the MALDI Biotyper (Bruker Daltonics) and Vitek MS
(BioMérieux) MALDI-TOF systems (I), MALDI Biotyper system using
database version 3.3.1.0 containing 4613 strains gave species- or genus-level
identification  with  score  value  ≥1.7  for  97  %  (149/151)  of  the  streptococcal
strains studied. 46 % of the strains (68/151) were identified using only direct
spotting and 54 % (81/151) using formic acid extraction by MALDI Biotyper.
VITEK  MS  identified  89  %  (135/151)  of  the  streptococcal  strains  with  an
acceptable confidence level (≥ 60 %). For 86 % of these strains (116/135), the
identification  was  reached  by  direct  colony  method,  whereas  14  % (19/135)
required on-target extraction with formic acid extraction for identification.
For the clinical VGS strains tested in the first part of this study, 95 of 97
strains had been identified at least to the group level (S. anginosus/S. bovis/S.
mitis/S. salivarius/S. sanguinis groups)  by  partial  sequencing  of  the  16S
rRNA  gene.  The  remaining  two  strains  were  ambiguously  identified  by
pyrosequencing as S. oralis/S. gallolyticus. These strains were identified by
both evaluated MALDI-TOF methods as S. parasanguinis.
For the streptococcal reference collection strains, MALDI Biotyper
correctly identified 94 % of them (51/54) to the species level. One reference
isolated remained unidentified and two type strains were misidentified.
Streptococcus infantarius ssp. infantarius CCUG43820 was misidentified by
MALDI Biotyper as Streptococcus equinus and Streptococcus mitis
DSM12643 as Streptococcus pneumoniae.  VITEK  MS  system  with  the
database version VITEK MS IVD v2 consistently identified 69 % (37/54) of the
streptococcal type strains. VITEK MS could provide no identification for 9 of
the 54 reference strains tested. Further eight reference strains were
misidentified by VITEK MS system when the database version VITEK MS IVD
v2  was  used.  For  two  of  the  non-identified  strains  and  three  of  the
misidentified strains correct identification could subsequently be obtained by
utilising the VITEK MS SARAMIS (RUO) database.
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Table 3. MALDI-TOF identification results of streptococcal strains used in this study
acquired by different MALDI-TOF instruments, database versions and algorithms (DB
= database, v. = version, N = number of strains, VGS = Viridans group streptococci,
MGS = Mitis group streptococci)
MALDI-
TOF
system
and
databas
e
version
VITEK MS
IVD DB v.
2
MALDI
Biotyper DB
v. 3.3.1.0
(4613
strains)
MALDI
Biotyper DB
v. 4.0.0.1
(5627
strains) with
log(score)
algorithm
MALDI
Biotyper DB
v. 4.0.0.1
(5627
strains) with
list(score)
algorithm
Publica
tion
n % n % n % n %
Streptococcal
strains yielding an
acceptable
identification a
I 135/1
51
89 149/151 97
II  299/299 100 299/299 100 299/299 100
Streptococcal
reference strains
correctly identified
to the group or
species level
I 37/54 69 51/54 94
Clinical VGS
strains identified
correctly to the
species group
levelb
I 88/97 93 85/97 89
Clinical VGS
strains correctly
identified to the
species levelc
I 35/36 97 27/36 75
Clinical Viridans
group non-
pneumococcal
strains misidentified
as S. pneumoniaed
I 0/97 0 36/97 37
S. pneumoniae
strains correctly
identified to the
species level
II  188/188 100 188/188 100 188/188 100
Clinical MGS
strains correctly
identified to the
species
group levele
I 63/63 0 27/63 43
II  35/101 35 100/101 99 101/101 100
a) ≥ 1.7 for MALDI Biotyper, ≥ 60 % for VITEK MS
b) 95 of the 97 clinical VGS strains had been identified at least to the species group level by
partial 16S rRNA sequencing
c) 36 of the 97 clinical VGS strains unequivocally identified to the species level by partial 16S
rRNA sequencing
d) All the strains misidentified as Streptococcus pneumoniae were identified as non-
pneumococcal S. mitis/S. sanguinis group species by partial 16S rRNA sequencing
e) All misidentified strains were misidentified as Streptococcus pneumoniae. The 10 strains
belonging to the S. sanguinis subgroup of MGS were excluded from this analysis, since
they were all correctly identified to the species level even when using the MALDI Biotyper
database version 3.3.1.0
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MALDI Biotyper identified 85 of the 97 clinical Viridans group strains used
in the first part of this study (89 %) and VITEK MS  88 (93 %) to the group
level consistently with the partial 16S rRNA gene sequencing.  Of the 36 strains
for which partial 16S rRNA sequencing had unequivocally suggested a species
level identification, MALDI Biotyper identified 27 (75 %) as the same species
as pyrosequencing. VITEK MS identified 35 of these 36 strains (97 %) to the
same species as partial 16S rRNA sequencing. One of the 36 strains could not
be identified by VITEK MS.
MALDI Biotyper misidentified 36 of the 97 clinical Viridans group
streptococcal strains included in the first part of this study as S. pneumoniae
(table  3).  In  contrast,  VITEK  MS  misidentified  none  of  these  strains  as S.
pneumoniae. All  the  clinical  Viridans  group  streptococcal  strains
misidentified  by  MALDI  Biotyper  had  been  identified  by  partial  16S  rRNA
sequencing as members of either S. mitis or S. sanguinis groups. (There were
altogether  63  strains  identified  by  pyrosequencing  as  belonging  to  these
groups included in the first part of this study, figure 3.) Optochin testing was
performed for all the strains identified as S. pneumoniae by MALDI Biotyper.
All but one of them proved to be optochin-resistant, which is consistent with
the pyrosequencing results. When re-examining the pyrosequencing data
(Haanperä et al. 2007), all these strains were also found to contain adenine at
the position 203 in 16S rRNA gene, which had been reported not to be the case
for S. pneumoniae by Scholz et al. in 2012.
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5.2 THE PERFORMANCE OF MALDI BIOTYPER AND
ABACUS GenomEra™ S. PNEUMONIAE TEST FOR
DIFFERENTIATION OF CLINICAL PNEUMOCOCCAL AND
MITIS GROUP STREPTOCOCCAL STRAINS (I, II, III)
In the first part of this study, a collection of 63 clinical streptococcal strains
identified as non-pneumococcal members of S. mitis species group (including
members of S. sanguinis subgroup)  by  partial  16S  rRNA  sequencing  were
identified  with  both  MALDI  Biotyper  with  database  version  3.3.1.0  (4613
strains)  (Bruker  Daltonics)  and  VITEK MS with  database  version  IVD vs.  2
(BioMérieux) MALDI-TOF systems in (I). MALDI Biotyper misidentified 36 of
these strains as S. pneumoniae,  whereas  VITEK  MS  misidentified  none  of
these strains as S. pneumoniae (table  3).  No  clinical  pneumococcal  strains
were included in this part of the study.
In the second part of this study (II), the effect of adopting an updated
database  version  (4.0.0.1,  5627  strains)  containing  an  increased  number  of
reference entries for S. pneumoniae, S. mitis and S. oralis (table 2) combined
with a novel identification algorithm (list(score)) for the ability of MALDI
Biotyper to differentiate between S. pneumoniae and other members S.
mitis/S. sanguinis group  streptococci  was  studied.  For  this  goal,  a  wider
selection of  111  clinical  Mitis/Sanguinis  group streptococcal  strains and 188
pneumococcal strains were identified using MALDI Biotyper system.
The results of assessment of the performance of MALDI Biotyper for
differentiation of pneumococci and mitis group streptococci using an
enhanced database and a novel result interpretation algorithm (II) are
summarized in Table 3. All S. pneumoniae strains were correctly identified as
S. pneumoniae with  all  MALDI  Biotyper  database  versions  and  both  the
standard log(score) algorithm and the novel list(score) algorithm. For the S.
mitis and S. sanguinis group strains, only 35/101 strains (35 %, 10  of which
were members of S. sanguinis subgroup) were correctly identified to the group
level  with  database  version  3.3.1  containing  4613  bacterial  strains  and
standard log(score) algorithm, whereas 66/101 (65 %) strains were
misidentified as S. pneumoniae, consistent with the results of the first part of
this study, in which 27 of the 63 S. mitis and S. sanguinis group strains tested
(75  %)  were  misidentified  using  the  same  database  version  and  algorithm
(table  3).  Using  the  newer  database  version  4.0.0.1  (5627  strains)  with  the
standard log(score) algorithm, only one of the 101 Mitis group strains tested
was misidentified, whereas even that strain was correctly identified when
combining the newer database version 4.0.0.1  (5627 strains)  with the novel
list(score) algorithm.
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For  the  evaluation  of  the  ability  of  the  ABACUS  GenomEra™ S.
pneumoniae nucleic acid amplification test to reliably differentiate between S.
pneumoniae and  other  members  of S. mitis/S. sanguinis species  group
streptococci (III), 37 clinical pneumococcal strains and 53 members of the S.
mitis/S. sanguinis species  group  also  isolated  from  clinical  infections  were
included in the third part of this study (figure 3). All 37 S. pneumoniae strains
included were positive for S. pneumoniae target in ABACUS GenomEra™ S.
pneumoniae assay, whereas all 44 S. mitis group streptococcal strains and 9 S.
sanguinis group  strains  gave  negative  results.  The  turnaround  time  to  the
results was 55 minutes.
5.3 THE PERFOMANCE OF ABACUS GenomEra™ S.
PNEUMONIAE TEST FOR DETECTION OF PNEUMOCOCCI
DIRECTLY FROM POSITIVE BLOOD CULTURE BOTTLES
(III)
For the evaluation of the performance of ABACUS GenomEra™
Pneumococcus test, detection of pneumococci directly from positive blood
culture  bottles,  46  of  the  110  positive  blood  culture  specimens  (41.8  %)  the
bacteria in the specimens were identified as S. pneumoniae by  VITEK  MS
(BioMérieux, Marcy-l’Etoile, France), Strep ID 32 (BioMérieux) and optochin
susceptibility testing. Other streptococcal species, enterococci, anaerobic
gram-positive cocci along with Acinetobacter lwoffii, Corynebacterium
amycolatum and Veillonella parvula were recovered from the remaining
positive  blood  culture  bottles  (64  specimens).  All  46  positive  blood  culture
specimens containing S. pneumoniae gave strongly positive (+100) signals for
S. pneumoniae target in ABACUS GenomEra™ S. pneumoniae assay, whereas
all 64 positive specimens containing other bacterial species remained negative
(signal  level  -15).  All  positive  blood  culture  specimens  containing S.
pneumoniae yielded positive results within 55 minutes.
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6   DISCUSSION
Rapid identification of Streptococcus pneumoniae using NAATs or
MALDI-TOF mass spectrometry has proven challenging because of  its  close
genetic relationship to streptococci belonging to Streptococcus
mitis/Streptococcus sanguinis group, which form an important part of normal
oral microbiota (Haanperä et al.  2007).  It  has also been reported in several
studies that differentiation between S. pneumoniae and S. mitis group
streptococci poses a challenge in direct identification of bacteria from positive
blood culture bottles using MALDI-TOF mass spectrometry (La Scola et al.
2009, Prod’hom et al. 2010, Kok et al. 2011, Farina et al. 2015). Direct
pneumococcal  antigen  testing  has  been  proposed  as  a  confirmatory  test  for
rapid identification of S. pneumoniae,  but false positive results caused by S.
mitis group streptococci cross-reacting with the pneumococcal C
polysaccharide antigen are common (Petti et al. 2005).
In the early studies on the ability of the MALDI-TOF mass spectrometry to
identify streptococci, identification of VGS remained unreliable, probably
largely  due  to  the  limited  number  of  VGS  strains  contained  in  the  earlier
versions of the databases of MALDI-TOF instruments (van Veen et al. 2010,
de Bel et al. 2010, Neville et al. 2011, Scholz et al. 2012, Martiny et al. 2012, ,
Davies et al. 2012, Lopez Roa et al. 2013, Ikryannikova et al. 2013, Dubois et
al. 2013, Branda et al. 2013, Woods et al. 2014).
Based  on  the  results  of  the  comparison  between  MALDI  Biotyper  with
database version 3.3.1.0 and VITEK MS with database version IVD vs. 2, VGS
species could be reliably identified to the group level (to S. anginosus group,
S. bovis group, S. mitis group, S. mutans group and S. salivarius groups) by
MALDI-TOF mass spectrometry. In contrast, reliable identification of VGS to
the species level within a specific group remained elusive (I). When using the
earlier database version 3.3.1.0 containing 4 613 reference entries, in which
only  a  few  reference  spectra  for  both S. pneumoniae and S. mitis group
streptococci were included, MALDI Biotyper (Bruker Daltonics) could not
sufficiently differentiate between these closely related species. Compared to
MALDI Biotyper with the earlier database version (containing 4613 database
entries), Vitek MS system with VITEK MS IVD database v2 (BioMérieux) was
better able to reliably distinguish between S. pneumoniae and S. mitis group
streptococci. This has also been found to be the case in the study by Angeletti
et al. (2015) carried out using the same database versions.  In their  study in
2015 Isaksson et al.  also found that among the VGS, MALDI-TOF had most
difficulties with the identification of the MGS.  On the other hand, for the VGS
as a whole, VITEK MS performed worse than MALDI Biotyper for species or
group level identification. This probably reflected the fact that at the time of
the study, compared to the MALDI Biotyper database, the VITEK MS database
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was weighed more towards the clinically most important bacterial species and
therefore contained more reference spectra for S. pneumoniae. Another factor
might have been the difference between the algorithm utilised by the two
MALDI-TOF mass spectrometry platforms. Whereas the standard log(score)
algorithm employed by MALDI Biotyper compares the whole sample spectrum
to the reference spectra in a similar manner, the algorithm employed in VITEK
MS  weighs  specific  peaks  in  the  mass  areas  showing  particularly  high
variability when calculating the identification results (Rychert et al. 2013).
Based  on  the  results  of  the  comparison  between  MALDI  Biotyper  with
database version 3.3.1.0 and VITEK MS with database version IVD vs. 2, we
hypothesized, that a combination of MALDI-TOF and NAAT identification
techniques might still be necessary in a clinical microbiology laboratory, since
obtaining good-quality mass spectra directly from blood culture bottles can
sometimes  be  more  challenging  for  streptococci  and  other  gram-positive
bacteria than for gram-negative bacteria (Kok et al. 2011). We therefore also
wanted to test a rapid automated NAAT ABACUS GenomEra S. pneumoniae
assay for confirmation of S. pneumoniae in conjunction with MALDI-TOF
mass spectrometry. The results proved that ABACUS GenomEra can reliably
distinguish between S. pneumoniae and S. mitis group streptococci directly
from positive blood culture bottles.  Since S. pneumoniae is  one of  the most
important pathogens causing bacteraemia, the ability to identify it quickly and
correctly also from positive blood culture bottles is of prime importance.
Because it was noticed that MALDI Biotyper misidentified most of the
Viridans group streptococci belonging to S. mitis and S. sanguinis groups as
S. pneumoniae when using the MALDI Biotyper database version 3.3.1
containing  4613  bacterial  strains,  we  decided  to  concentrate  on  the
differentiation between S. pneumoniae and S. mitis and S. sanguinis group
streptococci. We hypothesized that adding more S. pneumoniae and S. mitis
and S. sanguinis group streptococcal spectra to the MALDI Biotyper database
and/or  the  application  of  a  novel  list(score)  algorithm  tailored  to  the
differentiation between these bacteria might enhance the identification of
these closely related species.
The addition of 22 new S. pneumoniae strains, 38 new S. mitis strains and
34 new S. oralis strains  into  the  MALDI  Biotyper  database  version  4.0.0.1
(DB_5627) resulted in significantly improved differentiation between S.
pneumoniae and S. mitis and S. sanguinis group, with only one isolate of 101
misidentified as S. pneumoniae when using the DB_5627 with the standard
log(score)  algorithm.  When  using  the  DB_5627  with  the  novel  list(score)
algorithm,  all  the  S.  mitis/S.  sanguinis  group  strains  tested  were  identified
correctly  to  the  group  level.  This  was  also  the  case  when  using  the  newer
MALDI  Biotyper  database  version  DB_5989  with  the  standard  log(score)
algorithm.
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It is interesting to note that Slotved et al. (2017) received markedly worse
identification results in their study in which they had identified 47 S.
pneumoniae and  37  other  Mitis  group  streptococcal  strains  using  MALDI
Biotyper  with  a  newer  database  version  containing  6903  entries.  In  their
study,  all  pneumococcal  isolates  with  a  serotypeable  capsule  were  correctly
identified,  while  one  non-capsular  isolate  was  incorrectly  identified  as S.
pseudopneumoniae,  whereas  four  of  the  nine S. pseudopneumoniae strains
were incorrectly identified as S. pneumoniae.  Of the 20 S. mitis strains they
tested, three were misidentified as S. pneumoniae. This difference between
our and their results may be partially be explained by the fact that unlike us,
they did not perform formic acid extractions in addition to direct colony
spotting. However, the difference is probably also largely due to the fact that
their  set  of  MGS  strains  contained  nine  strains  of S. pseudopneumoniae,
whereas  none  of  the  clinical  strains  in  our  study  was  identified  as S.
pseudopneumoniae by partial 16S rRNA sequencing or recA gene sequencing.
There were also no non-serotypeable S. pneumoniae strains  among  our
clinical  isolates,  whereas  in  their  study  25  of  the  47 S. pneumoniae strains
tested were non-capsular and therefore non-serotypeable. The lack of S.
pseudopneumoniae and non-capsular S. pneumoniae strains  among  our
clinical strains, which were isolated from invasive infections supports the
notion that S. pseudopneumoniae and non-capsular pneumococci are
typically not involved in invasive infections (Park et al. 2014, Keller et al. 2016
(2), Bradshaw et al. 2018). In another study by van Prehn et al. (2016) it was
also  found  that  MALDI  Biotyper  (with  database  version  containing  5627)
misidentified three of the 13 S. pseudopneumoniae tested as S.
pseudopneumoniae,  in contrast  to VITEK MS, which identified correctly  all
the S. pseudopneumoniae strains  tested  in  their  study.  Although  the
difficulties with reliable identification of S. pseudopneumoniae are not
probably highly relevant for diagnosis of invasive infections, they are probably
more relevant when detecting pneumococcal carriage.
Several authors have also suggested detection of specific peaks in order to
help with the differentiation of S. pneumoniae and MGS and aiding in species-
level identification of non-pneumococcal MGS (Werno et al. 2012,
Ikryannikova et al. 2013, Chen et al. 2015, Marín et al. 2018). Although useful
for  research  laboratories,  adoption  of  such  closer  analysis  of  the  sample
spectra in a clinical microbiology laboratory would require a more automated
data analysis than is currently available. The results of the studies detecting
specific peaks also seem generally less reproducible than identification results
based on the analysis of the whole protein spectra, probably because the exact
mass  of  a  single  peak  is  more  sensitive  to  intraspecies  variations  and
differences in growth conditions.
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7 CONCLUSIONS AND FUTURE
PERSPECTIVES
Our  study  has  shown that  VGS streptococci  can  reliably  be  identified  to
group level (to S. anginosus group, S. bovis group, S. mitis group, S. mutans
group or S. salivarius group) by MALDI-TOF mass spectrometry. S.
pneumoniae and S. mitis group streptococci can also be reliably distinguished
from each other by MALDI-TOF mass spectrometry when using a database
containing reference spectra of several species of both S. pneumoniae and S.
mitis group streptococci, preferably combined with an identification algorithm
weighing first few reference matches, such as list-score algorithm tested in the
third part of this study for MALDI Biotyper, or weighing specific peaks when
calculating the identification results, such as the algorithm employed in
VITEK MS (Rychert et al. 2013).
Based on the results of our study, we would suggest that including more S.
pneumoniae and S. mitis group streptococci in the databases of MALDI-TOF
mass spectrometry instruments and developing specific algorithms has
significantly  improved  the  ability  of  MALDI  Biotyper  system  to  distinguish
between these closely related streptococci, allowing for reliable differentiation
of S. pneumoniae and S. mitis group streptococci colonies from culture plates.
It would also be interesting to know whether the application of the list(score)
algorithm tested in this study would aid in more reliably identifying even S.
pseudopneumoniae strains,  which  were  unfortunately  not  included  in  our
study sample.
In  addition  to  MALDI-TOF  mass  spectrometry,  adoption  of  rapid
automated NAATs such as ABACUS Genomera S. pneumoniae evaluated in
this study also have the potential to significantly accelerate the identification
of S. pneumoniae. Combining MALDI-TOF mass spectrometry and such rapid
targeted NAATs for identification of streptococci directly from positive blood
culture bottles could enable their  identification within an hour of  the blood
culture  system  has  signalled  for  growth,  whereas  identification  of S.
pneumoniae and VGS using traditional biochemical identification methods
typically  takes two days after  growth has been detected in the blood culture
bottle. In the future, it would be interesting to evaluate the effect that the
adaption of a rapid identification strategy combining MALDI-TOF mass
spectrometry with NAATs performed directly from positive blood culture
bottles has had for the turn-around time for the identification of streptococci
in  a  clinical  microbiology  laboratory.  In  near  future,  it  may  be  possible  to
accelerate the identification process even further by utilising more sensitive
NAATs that can identify bacteria directly from patient’s blood without need
for enrichment by blood culture. Combination of MALDI-TOF or electron-
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spray ionization mass spectrometry (ESI-MS) with other technologies such as
flow  cytometry  or  chromatography  also  hold  potential  for  faster  and  more
accurate infection diagnostics.
Accurate species-level identification among non-pneumococcal S. mitis
group or  other  VGS strains  will  likely  remain  an  elusive  goal  even  with  the
development of even more sophisticated molecular identification methods in
the future. This is a result of their nature as a very variable species group or
species spectrum for which human-imposed species definitions, which don’t
consider the extent of horizontal gene transfer and genome rearrangements
likely happening within even the same strain over time, are ill-fitting. This is
to a lesser degree true also for other Viridans group streptococci,  for  which
reliable  group  level  identification  can  be  obtained  by  MALDI-TOF  mass
spectrometry, but for many of which more detailed species-level identification
has  also  proven  challenging,  even  when  using  such  laborious  and  time-
consuming methods as MLST.
Fortunately, for Viridans group streptococci, group-level identification
seems to be enough for the purpose of evaluating the clinical significance of
the isolated organism, since members of the same species group tend to reside
in similar sites in the human body and resemble each other in their pathogenic
potential.  After 75 years and countless technological innovations in the field
of microbiology, these words of Sherman et al. on Viridans group streptococci
in the seminal paper of 1943 still ring true: “It is idle to try to define a "species"
of  bacteria,  or  even  say  whether  or  not  such  an  entity  can  be  defined…
However, the classification of bacteria is of value for practical purposes, the
"species" being units which can be identified and differentiated from other
closely related groups with some degree of certainty and ease… Although
tedious and detailed studies are essential in order to define more definitely the
limits  of  a  species,  the  main  value  of  such  work  as  this  is  to  arrive  at  some
simple  tests  which  can  be  applied  in  the  practical  problem  of  quickly
identifying the organism.”
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